Gene	Gene synonym	Ensembl	Gene description	Chromosome	Position	Protein class	Evidence	Antibody	Reliability (IH)	Reliability (Mouse Brain)	Reliability (IF)	Subcellular location	Prognostic p-value	RNA cancer category	RNA tissue category	RNA TS	RNA TS TPM	TPM max in non-specific	RNA cell line category	RNA CS	RNA CS TPM
ZNF385B	FLJ25270, ZNF533	ENSG00000144331	Zinc finger protein 385B	2	179441982-179861505	Predicted intracellular proteins	Evidence at protein level	HPA046086			Supported	Nucleoli fibrillar center	Renal cancer:1.04e-9 (favourable), Breast cancer:4.86e-8 (favourable)	Group enriched	Tissue enhanced		lung: 27.5	prostate: 20.0	Cell line enhanced		Daudi: 12.3;HAP1: 32.8;U-698: 60.0
TFPI2	PP5, REF1, TFPI-2	ENSG00000105825	Tissue factor pathway inhibitor 2	7	93885397-93890991	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB010142, HPA049158	Enhanced				Breast cancer:8.33e-7 (favourable), Endometrial cancer:5.42e-4 (favourable), Renal cancer:8.53e-4 (unfavourable)	Expressed in all	Tissue enriched	23	placenta: 1208.2	ovary: 52.0	Cell line enhanced		EFO-21: 1987.5;hTEC/SVTERT24-B: 1055.6;U-138 MG: 999.0;U-2197: 850.7;U-87 MG: 1680.0
IL27RA	CRL1, IL-27R, TCCR, WSX-1, WSX1, zcytor1	ENSG00000104998	Interleukin 27 receptor subunit alpha	19	14031748-14053216	Predicted membrane proteins	Evidence at protein level						Renal cancer:2.58e-10 (unfavourable), Breast cancer:1.74e-6 (favourable)	Expressed in all	Mixed			tonsil: 30.4	Mixed		
JCHAIN	IGCJ, IGJ, JCH	ENSG00000132465	Joining chain of multimeric IgA and IgM	4	70655541-70681817	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB034436, HPA044132	Enhanced				Head and neck cancer:7.56e-7 (favourable), Breast cancer:1.81e-6 (favourable), Renal cancer:1.40e-4 (unfavourable)	Expressed in all	Expressed in all			colon: 6965.1	Group enriched	205	Daudi: 2569.0;Karpas-707: 1336.5;RPMI-8226: 2653.0;U-266/70: 5934.2;U-266/84: 2263.1;U-698: 3199.2
ARID5A	MRF-1, RP11-363D14	ENSG00000196843	AT-rich interaction domain 5A	2	96536743-96552638	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002860, HPA023879	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:4.24e-8 (unfavourable), Breast cancer:2.05e-6 (favourable)	Expressed in all	Expressed in all			appendix: 25.4	Group enriched	6	HDLM-2: 239.9;RPMI-8226: 78.9
MAP2K6	MAPKK6, MEK6, MKK6, PRKMK6, SAPKK3	ENSG00000108984	Mitogen-activated protein kinase kinase 6	17	69414698-69543331	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB007744, HPA031134	Enhanced		Supported	Nucleus<br>Cytosol	Breast cancer:2.27e-6 (favourable), Pancreatic cancer:7.52e-4 (favourable)	Mixed	Mixed			cervix, uterine: 39.1	Cell line enhanced		A549: 36.5
NEFH		ENSG00000100285	Neurofilament heavy	22	29480230-29491390	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB007786, HPA061615	Enhanced		Approved	Nucleoli<br>Cytosol	Breast cancer:2.33e-6 (favourable)	Group enriched	Tissue enriched	11	prostate: 405.8	cerebral cortex: 37.3	Cell line enriched	6	SiHa: 193.4
DEF6	IBP, SLAT, SWAP70L	ENSG00000023892	DEF6, guanine nucleotide exchange factor	6	35297852-35321771	Predicted intracellular proteins	Evidence at protein level	HPA038975, HPA038976	Enhanced		Enhanced	Nucleoplasm	Renal cancer:1.02e-8 (unfavourable), Breast cancer:3.02e-6 (favourable), Cervical cancer:1.08e-4 (favourable), Colorectal cancer:1.71e-4 (unfavourable), Endometrial cancer:2.37e-4 (favourable)	Expressed in all	Mixed			lymph node: 56.1	Cell line enhanced		U-937: 93.5
C6orf141	MGC46457	ENSG00000197261	Chromosome 6 open reading frame 141	6	49550646-49561907	Predicted intracellular proteins	Evidence at protein level	HPA036199	Uncertain		Approved	Nuclear membrane	Breast cancer:3.92e-6 (favourable), Endometrial cancer:1.15e-4 (favourable)	Mixed	Tissue enhanced		gallbladder: 9.3	duodenum: 6.2	Cell line enhanced		HaCaT: 7.6;PC-3: 10.6;T-47d: 6.8
CA3	CAIII, Car3	ENSG00000164879	Carbonic anhydrase 3	8	85373436-85449040	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004967, HPA021775, HPA026700	Enhanced				Breast cancer:4.24e-6 (favourable)	Group enriched	Tissue enriched	13	skeletal muscle: 1838.7	prostate: 138.3	Group enriched	34	HEL: 44.2;RH-30: 77.2
GSTK1	GST13	ENSG00000197448	Glutathione S-transferase kappa 1	7	143244093-143270854	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006311, HPA022904	Enhanced		Supported	Peroxisomes	Renal cancer:2.10e-6 (favourable), Breast cancer:4.41e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 377.4	Expressed in all		
PEX10	RNF69	ENSG00000157911	Peroxisomal biogenesis factor 10	1	2403964-2413797	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA049458, HPA049755	Approved		Approved	Nucleoplasm	Renal cancer:4.16e-6 (favourable), Breast cancer:4.50e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 19.2	Expressed in all		
SGK3	SGK2, SGKL	ENSG00000104205	Serum/glucocorticoid regulated kinase family member 3	8	66712418-66862022	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006699, HPA027146	Supported		Approved	Nucleoplasm<br>Vesicles	Breast cancer:5.52e-6 (favourable), Cervical cancer:8.28e-4 (favourable), Pancreatic cancer:9.65e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 48.5	Mixed		
SLC5A8	AIT	ENSG00000256870	Solute carrier family 5 member 8	12	101155493-101210407	Predicted membrane proteins	Evidence at protein level						Breast cancer:9.04e-6 (favourable), Renal cancer:1.97e-4 (favourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 15.0;thyroid gland: 14.7	kidney: 3.5	Cell line enriched	6	SK-BR-3: 2.3
RAC2	EN-7	ENSG00000128340	Ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2)	22	37225261-37244448	Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB022946, HPA047820	Approved				Renal cancer:1.06e-6 (unfavourable), Breast cancer:1.03e-5 (favourable)	Expressed in all	Expressed in all			lymph node: 443.7	Cell line enhanced		HL-60: 579.7;HMC-1: 1246.3;U-87 MG: 600.7
PIGR		ENSG00000162896	Polymeric immunoglobulin receptor	1	206928518-206946466	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA006154, CAB009454, HPA012012	Enhanced				Breast cancer:1.22e-5 (favourable), Renal cancer:5.08e-5 (favourable), Endometrial cancer:2.57e-4 (favourable)	Tissue enhanced	Tissue enhanced		colon: 1688.0;duodenum: 2659.3	rectum: 1335.9	Cell line enriched	7	EFO-21: 33.8
ZMYM6	Buster2, MYM, ZBED7, ZNF198L4, ZNF258	ENSG00000163867	Zinc finger MYM-type containing 6	1	34986165-35031968	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011004, HPA071865	Approved		Supported	Nucleoplasm	Breast cancer:1.30e-5 (favourable)	Expressed in all	Mixed			testis: 19.0	Expressed in all		
NFKBIA	IkappaBalpha, IKBA, MAD-3, NFKBI	ENSG00000100906	NFKB inhibitor alpha	14	35401511-35404749	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB003815, HPA029207	Approved		Enhanced	Cytosol	Breast cancer:1.33e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 711.6	Expressed in all		
TNFRSF17	BCM, BCMA, CD269, TNFRSF13A	ENSG00000048462	TNF receptor superfamily member 17	16	11965107-11968068	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Head and neck cancer:1.58e-6 (favourable), Breast cancer:1.35e-5 (favourable)	Mixed	Tissue enhanced		tonsil: 36.7	lymph node: 30.8	Group enriched	7	Karpas-707: 114.0;RPMI-8226: 179.8;U-266/70: 561.8;U-266/84: 274.9
RARRES3	HRASLS4, TIG3	ENSG00000133321	Retinoic acid receptor responder 3	11	63536809-63546462	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Pancreatic cancer:6.26e-6 (unfavourable), Breast cancer:1.35e-5 (favourable), Cervical cancer:4.00e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 166.5	Cell line enhanced		CAPAN-2: 203.5;RPTEC TERT1: 87.4;SK-BR-3: 131.4
SERPINA1	A1A, A1AT, AAT, alpha-1-antitrypsin, alpha1AT, PI, PI1	ENSG00000197249	Serpin family A member 1	14	94376747-94390693	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000927, HPA001292, CAB013211, CAB016648, CAB073396	Enhanced		Enhanced	Vesicles	Breast cancer:1.61e-5 (favourable), Colorectal cancer:5.86e-4 (favourable)	Tissue enriched	Tissue enriched	20	liver: 17144.0	small intestine: 857.0	Cell line enriched	6	Hep G2: 3254.2
NFKBIE	IKBE	ENSG00000146232	NFKB inhibitor epsilon	6	44258166-44265788	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002692, HPA005941, CAB010272	Supported		Supported	Nucleus<br>Nucleoli fibrillar center<br>Cytosol	Renal cancer:1.37e-6 (unfavourable), Breast cancer:1.72e-5 (favourable), Liver cancer:3.50e-4 (unfavourable), Urothelial cancer:8.07e-4 (favourable)	Expressed in all	Mixed			spleen: 26.1	Expressed in all		
TRAPPC12	CGI-87, TTC-15, TTC15	ENSG00000171853	Trafficking protein particle complex 12	2	3379675-3485094	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034799	Uncertain				Breast cancer:1.80e-5 (favourable), Renal cancer:2.44e-4 (unfavourable), Pancreatic cancer:9.15e-4 (favourable)	Expressed in all	Expressed in all			testis: 48.7	Expressed in all		
CD52	CDW52	ENSG00000169442	CD52 molecule	1	26317957-26320523	Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level						Breast cancer:1.85e-5 (favourable), Endometrial cancer:2.06e-4 (favourable), Head and neck cancer:4.45e-4 (favourable), Renal cancer:5.85e-4 (unfavourable)	Expressed in all	Tissue enriched	35	epididymis: 43887.5	lymph node: 1251.0	Group enriched	8	Daudi: 505.6;REH: 946.6;U-266/84: 745.1;U-698: 783.6
RASGEF1A	CG4853, FLJ37817	ENSG00000198915	RasGEF domain family member 1A	10	43194535-43266919	Predicted intracellular proteins	Evidence at protein level	HPA035593	Enhanced		Approved	Golgi apparatus	Renal cancer:4.11e-7 (unfavourable), Breast cancer:1.86e-5 (favourable), Endometrial cancer:4.28e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 22.7	parathyroid gland: 12.8	Cell line enhanced		K-562: 15.4;SCLC-21H: 18.4;T-47d: 14.7
C6orf226	LOC441150	ENSG00000221821	Chromosome 6 open reading frame 226	6	42890265-42890816	Predicted intracellular proteins	Evidence at protein level	HPA045350	Approved		Approved	Nuclear speckles	Breast cancer:1.93e-5 (favourable), Renal cancer:3.35e-4 (favourable), Pancreatic cancer:5.13e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 13.4	Mixed		
TIPARP	DDF1, DKFZP434J214, DKFZp686N0351, PARP-1, PARP-7, PARP7, pART14, RM1	ENSG00000163659	TCDD inducible poly(ADP-ribose) polymerase	3	156673235-156706770	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA036796	Uncertain		Approved	Microtubules	Breast cancer:2.00e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 232.4	Expressed in all		
CEBPD	C/EBP-delta, CELF, CRP3, NF-IL6-beta	ENSG00000221869	CCAAT/enhancer binding protein delta	8	47736909-47739086	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067581			Supported	Nucleoplasm	Renal cancer:2.87e-7 (unfavourable), Breast cancer:2.28e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 71.1	Cell line enhanced		HHSteC: 29.5;NB-4: 50.0;SiHa: 33.7
BEND5	C1orf165, FLJ11588	ENSG00000162373	BEN domain containing 5	1	48727523-48776969	Predicted intracellular proteins	Evidence at protein level	HPA054347, HPA058007	Uncertain				Urothelial cancer:8.30e-6 (favourable), Breast cancer:2.50e-5 (favourable), Pancreatic cancer:1.29e-4 (favourable), Lung cancer:1.29e-4 (favourable)	Mixed	Mixed			cerebral cortex: 6.0	Cell line enhanced		AF22: 3.2;HDLM-2: 10.2;MOLT-4: 3.6;REH: 5.7;SH-SY5Y: 3.1
ARL14EP	ARF7EP, C11orf46, FLJ38968	ENSG00000152219	ADP ribosylation factor like GTPase 14 effector protein	11	30323051-30338227	Predicted intracellular proteins	Evidence at protein level	HPA039634, HPA048127	Approved		Approved	Nucleus<br>Vesicles<br>Focal adhesion sites<br>Cytosol	Breast cancer:2.50e-5 (favourable), Liver cancer:5.26e-4 (unfavourable), Urothelial cancer:7.49e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 53.5	Expressed in all		
APOBEC3D	APOBEC3DE, APOBEC3E, ARP6	ENSG00000243811	Apolipoprotein B mRNA editing enzyme catalytic subunit 3D	22	39021113-39033276	Predicted intracellular proteins	Evidence at protein level	HPA055116	Uncertain				Renal cancer:3.76e-7 (unfavourable), Breast cancer:2.51e-5 (favourable), Cervical cancer:1.31e-4 (favourable), Urothelial cancer:3.01e-4 (favourable), Endometrial cancer:4.47e-4 (favourable)	Expressed in all	Mixed			lymph node: 15.1	Cell line enhanced		Karpas-707: 31.5
KRTCAP3	KCP3	ENSG00000157992	Keratinocyte associated protein 3	2	27442366-27446481	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047136, HPA060203	Enhanced		Approved	Nucleus<br>Cytosol	Breast cancer:2.67e-5 (favourable)	Expressed in all	Mixed			small intestine: 34.8	Cell line enhanced		A-431: 53.9;CAPAN-2: 60.3;SCLC-21H: 37.2
CFB	BF, BFD, H2-Bf	ENSG00000243649	Complement factor B	6	31945650-31952084	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000951, HPA001817, HPA001832, CAB016381	Supported		Approved	Endoplasmic reticulum<br>Vesicles<br>Cell Junctions	Renal cancer:1.53e-5 (unfavourable), Breast cancer:2.76e-5 (favourable)	Expressed in all	Tissue enriched	21	liver: 285.9	stomach: 13.8	Cell line enhanced		CAPAN-2: 6.6;fHDF/TERT166: 9.6;HSkMC: 14.1
CCL19	CKb11, ELC, exodus-3, MIP-3b, SCYA19	ENSG00000172724	C-C motif chemokine ligand 19	9	34689567-34691277	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA067758	Enhanced				Renal cancer:8.63e-7 (unfavourable), Cervical cancer:9.91e-6 (favourable), Breast cancer:2.88e-5 (favourable)	Expressed in all	Group enriched	5	adipose tissue: 173.8;appendix: 771.8;lymph node: 703.2;tonsil: 556.0	gallbladder: 107.9	Cell line enhanced		HDLM-2: 2.9;TIME: 1.2
SNX22	FLJ13952	ENSG00000157734	Sorting nexin 22	15	64151715-64157481	Predicted intracellular proteins	Evidence at protein level	HPA038470	Approved		Approved	Nucleoplasm<br>Vesicles	Breast cancer:2.89e-5 (favourable), Thyroid cancer:2.19e-4 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 16.2;thyroid gland: 14.4	lymph node: 9.0	Cell line enhanced		Daudi: 13.5;SCLC-21H: 4.9
SAV1	salvador, WW45, WWP4	ENSG00000151748	Salvador family WW domain containing protein 1	14	50632058-50668331	Predicted intracellular proteins	Evidence at protein level	HPA001808	Approved		Supported	Cytosol	Renal cancer:3.83e-6 (favourable), Breast cancer:2.92e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 58.3	Expressed in all		
CCDC24	MGC45441	ENSG00000159214	Coiled-coil domain containing 24	1	43991359-43996528	Predicted intracellular proteins	Evidence at protein level	HPA035424, HPA061710	Uncertain		Enhanced	Plasma membrane<br>Cytosol	Breast cancer:3.06e-5 (favourable), Liver cancer:1.70e-4 (unfavourable), Head and neck cancer:3.18e-4 (favourable)	Expressed in all	Tissue enhanced		fallopian tube: 18.3	testis: 15.2	Cell line enhanced		CAPAN-2: 11.7
KYAT3	CCBL2, KAT3, KATIII, RBM1, RP11-82K18.3	ENSG00000137944	Kynurenine aminotransferase 3	1	88935773-88992953	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026538, HPA027168	Enhanced		Approved	Nucleoli<br>Cytosol	Renal cancer:5.02e-6 (favourable), Breast cancer:3.19e-5 (favourable), Head and neck cancer:1.86e-4 (favourable), Ovarian cancer:2.80e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 42.8	Expressed in all		
CD69	CLEC2C	ENSG00000110848	CD69 molecule	12	9752486-9760901	CD markers, Predicted membrane proteins	Evidence at protein level	CAB002503, HPA050525	Enhanced				Breast cancer:3.31e-5 (favourable), Renal cancer:7.87e-5 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 105.9;lymph node: 109.1	appendix: 64.1	Cell line enhanced		HL-60: 23.7;K-562: 52.0;U-937: 76.0
STOX1	C10orf24, FLJ25162	ENSG00000165730	Storkhead box 1	10	68827541-68895432	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA037844, HPA037845	Approved		Supported	Nucleoplasm<br>Nucleoli fibrillar center<br>Cytosol	Breast cancer:3.37e-5 (favourable), Lung cancer:2.08e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 20.0	cerebral cortex: 14.0	Cell line enhanced		AN3-CA: 8.0;HAP1: 8.3
KLRB1	CD161, CLEC5B, hNKR-P1A, NKR, NKR-P1, NKR-P1A	ENSG00000111796	Killer cell lectin like receptor B1	12	9594551-9607886	CD markers, Predicted membrane proteins	Evidence at protein level	HPA039113	Approved		Uncertain	Nucleoplasm<br>Cytosol	Endometrial cancer:1.42e-5 (favourable), Breast cancer:3.51e-5 (favourable), Head and neck cancer:6.99e-5 (favourable), Thyroid cancer:5.61e-4 (favourable)	Mixed	Mixed			spleen: 40.7	Not detected		
TOPORS-AS1	C9orf133	ENSG00000235453	TOPORS antisense RNA 1	9	32551144-32567005	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level						Breast cancer:4.18e-5 (favourable), Pancreatic cancer:7.33e-5 (favourable), Renal cancer:3.46e-4 (favourable), Cervical cancer:6.11e-4 (favourable), Ovarian cancer:8.39e-4 (favourable)	Expressed in all	Expressed in all			testis: 35.7	Mixed		
ENDOV	FLJ35220	ENSG00000173818	Endonuclease V	17	80415165-80438086	Predicted intracellular proteins	Evidence at protein level						Breast cancer:4.24e-5 (favourable), Colorectal cancer:4.40e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 22.2	Mixed		
MS4A1	B1, Bp35, CD20, MS4A2	ENSG00000156738	Membrane spanning 4-domains A1	11	60455752-60470760	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB000015, HPA014341, HPA014391	Enhanced		Supported	Plasma membrane	Breast cancer:4.34e-5 (favourable)	Mixed	Group enriched	15	appendix: 240.0;lymph node: 770.3;spleen: 468.8;tonsil: 789.8	urinary bladder: 38.3	Group enriched	19	Daudi: 534.8;U-698: 258.0
BTG1	APRO2	ENSG00000133639	BTG anti-proliferation factor 1	12	92140278-92145897	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA005972			Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.95e-7 (unfavourable), Breast cancer:4.36e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 261.0	Expressed in all		
TNFRSF14	ATAR, CD270, HVEA, HVEM, LIGHTR, TR2	ENSG00000157873	TNF receptor superfamily member 14	1	2555639-2565382	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA006404, CAB026150, CAB030007	Approved		Approved	Cytosol<br>Rods & Rings	Urothelial cancer:7.79e-6 (favourable), Endometrial cancer:8.01e-6 (favourable), Breast cancer:4.39e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 45.5	Cell line enhanced		CAPAN-2: 23.4;HDLM-2: 25.7;HHSteC: 25.4;SK-MEL-30: 41.0
SPIB	SPI-B	ENSG00000269404	Spi-B transcription factor	19	50418938-50431313	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018523	Uncertain				Head and neck cancer:2.14e-5 (favourable), Breast cancer:4.76e-5 (favourable)	Mixed	Tissue enhanced		appendix: 53.9;lymph node: 103.3;tonsil: 91.1	spleen: 39.2	Group enriched	10	Daudi: 119.1;HDLM-2: 99.4;Karpas-707: 37.4;U-698: 159.1
MYBPC1		ENSG00000196091	Myosin binding protein C, slow type	12	101568353-101686018	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021004, HPA027614	Enhanced				Breast cancer:4.76e-5 (favourable)	Tissue enhanced	Tissue enriched	31	skeletal muscle: 3918.4	prostate: 125.8	Not detected		
TRIM21	RNF81, Ro/SSA, RO52, SSA1	ENSG00000132109	Tripartite motif containing 21	11	4384897-4393696	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004566, HPA005673	Approved		Approved	Nucleoplasm	Thyroid cancer:2.26e-6 (favourable), Breast cancer:4.83e-5 (favourable), Liver cancer:1.87e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 41.2	Mixed		
C17orf107		ENSG00000205710	Chromosome 17 open reading frame 107	17	4899418-4902932	Predicted intracellular proteins	Evidence at transcript level	HPA069713	Uncertain		Approved	Nucleus	Breast cancer:5.06e-5 (favourable), Renal cancer:2.68e-4 (favourable), Pancreatic cancer:8.61e-4 (favourable)	Mixed	Mixed			parathyroid gland,salivary gland: 5.7	Cell line enhanced		fHDF/TERT166: 2.2;HMC-1: 3.2;hTCEpi: 2.4
FAM117A		ENSG00000121104	Family with sequence similarity 117 member A	17	49710332-49789180	Predicted intracellular proteins	Evidence at protein level	HPA022531	Approved		Approved	Nucleoplasm	Lung cancer:8.25e-7 (favourable), Breast cancer:5.30e-5 (favourable), Pancreatic cancer:1.81e-4 (favourable)	Expressed in all	Expressed in all			spleen: 46.6	Cell line enhanced		U-266/70: 61.5
ADHFE1	ADHFe1, FLJ32430	ENSG00000147576	Alcohol dehydrogenase, iron containing 1	8	66430185-66471601	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023062	Enhanced		Approved	Vesicles	Renal cancer:4.55e-5 (favourable), Breast cancer:5.76e-5 (favourable), Liver cancer:9.90e-5 (favourable)	Mixed	Mixed			liver: 14.3	Cell line enhanced		ASC diff: 1.1;RPTEC TERT1: 1.2
TPT1	fortilin, TCTP	ENSG00000133112	Tumor protein, translationally-controlled 1	13	45333471-45341370	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008364, HPA039437	Approved		Supported	Cytosol	Renal cancer:2.54e-5 (unfavourable), Thyroid cancer:4.31e-5 (favourable), Breast cancer:5.90e-5 (favourable), Endometrial cancer:2.35e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 8103.8	Expressed in all		
CXCL2	CINC-2a, GRO2, GROb, MGSA-b, MIP-2a, SCYB2	ENSG00000081041	C-X-C motif chemokine ligand 2	4	74097035-74099293	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:2.07e-6 (unfavourable), Breast cancer:5.93e-5 (favourable), Cervical cancer:1.41e-4 (unfavourable)	Expressed in all	Tissue enhanced		liver: 110.2	lung: 95.2	Cell line enhanced		BJ hTERT+: 38.3;HHSteC: 26.8;hTCEpi: 24.9;hTEC/SVTERT24-B: 24.7;hTERT-HME1: 25.6;U-87 MG: 27.5
CLIC6	CLIC1L, CLIC5	ENSG00000159212	Chloride intracellular channel 6	21	34669389-34718227	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA055123, HPA065285	Enhanced				Lung cancer:3.15e-5 (favourable), Breast cancer:6.11e-5 (favourable)	Mixed	Tissue enhanced		stomach: 79.1	cervix, uterine: 24.4	Cell line enhanced		HMC-1: 2.4;NTERA-2: 3.8;T-47d: 7.2;THP-1: 2.3
JUND	AP-1	ENSG00000130522	JunD proto-oncogene, AP-1 transcription factor subunit	19	18279760-18281622	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB005268, HPA063029	Supported		Supported	Nucleus	Breast cancer:6.15e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 277.7	Expressed in all		
PARP3	ADPRT3, ADPRTL3, hPARP-3, IRT1, pADPRT-3	ENSG00000041880	Poly(ADP-ribose) polymerase family member 3	3	51942345-51948867	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA067657	Supported				Renal cancer:1.25e-8 (favourable), Breast cancer:6.39e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 53.0	Expressed in all		
ALKBH2	ABH2, MGC90512	ENSG00000189046	AlkB homolog 2, alpha-ketoglutarate dependent dioxygenase	12	109088188-109093631	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB011198, HPA045392, HPA051976	Approved		Enhanced	Nucleus	Renal cancer:1.41e-5 (unfavourable), Breast cancer:6.67e-5 (favourable), Urothelial cancer:8.67e-4 (favourable)	Expressed in all	Expressed in all			skin: 27.0	Expressed in all		
ELOVL2	Ssc2	ENSG00000197977	ELOVL fatty acid elongase 2	6	10980759-11044314	Enzymes, Predicted membrane proteins	Evidence at protein level						Breast cancer:6.73e-5 (favourable)	Group enriched	Tissue enhanced		liver: 27.6;parathyroid gland: 36.7;placenta: 50.2	cerebral cortex: 22.8	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 29.1;HBF TERT88: 28.0;RH-30: 30.7
NME3	DR-nm23, NDPKC, NM23-H3	ENSG00000103024	NME/NM23 nucleoside diphosphate kinase 3	16	1770286-1771730	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041113, HPA052733	Approved		Approved	Nucleoplasm<br>Cytosol	Breast cancer:6.81e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 36.1	Cell line enhanced		HEK 293: 64.8
IRF2		ENSG00000168310	Interferon regulatory factor 2	4	184387713-184474580	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030813, CAB032306, HPA057327	Supported		Enhanced	Nucleoplasm<br>Cytosol	Breast cancer:6.95e-5 (favourable), Thyroid cancer:8.34e-5 (favourable)	Expressed in all	Expressed in all			spleen: 74.2	Expressed in all		
GRHPR	GLXR, PH2	ENSG00000137106	Glyoxylate and hydroxypyruvate reductase	9	37422666-37436990	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022971	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.39e-9 (favourable), Breast cancer:7.00e-5 (favourable)	Expressed in all	Expressed in all			liver: 323.3	Expressed in all		
EGR2	KROX20	ENSG00000122877	Early growth response 2	10	62811996-62919900	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031165			Supported	Nucleoplasm	Breast cancer:7.30e-5 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 234.3	epididymis: 73.8	Cell line enriched	7	U-87 MG: 22.2
PHF7	HSPC226, NYD-SP6	ENSG00000010318	PHD finger protein 7	3	52410657-52423641	Predicted intracellular proteins	Evidence at protein level	HPA036283, HPA070305	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.05e-6 (favourable), Breast cancer:7.38e-5 (favourable), Endometrial cancer:9.44e-5 (favourable)	Expressed in all	Tissue enriched	432	testis: 2183.4	rectum: 5.0	Cell line enhanced		U-266/70: 13.2
STC2	STC-2	ENSG00000113739	Stanniocalcin 2	5	173314713-173329503	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045372	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:4.17e-8 (unfavourable), Head and neck cancer:1.76e-6 (unfavourable), Liver cancer:3.07e-5 (unfavourable), Breast cancer:7.40e-5 (favourable), Stomach cancer:7.57e-4 (unfavourable)	Tissue enriched	Tissue enhanced		breast: 164.6	placenta: 33.2	Cell line enhanced		LHCN-M2: 707.5;T-47d: 753.9;U-138 MG: 321.3
GNA15	GNA16	ENSG00000060558	G protein subunit alpha 15	19	3136193-3163769	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043113	Approved				Renal cancer:4.26e-6 (unfavourable), Breast cancer:7.57e-5 (favourable), Endometrial cancer:2.01e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 48.7;esophagus: 61.3	skin: 25.9	Cell line enhanced		HMC-1: 142.1;MOLT-4: 137.5;REH: 115.4
NPY1R	NPYR	ENSG00000164128	Neuropeptide Y receptor Y1	4	163323961-163344832	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029903			Approved	Nucleus<br>Mitochondria<br>Cytosol	Breast cancer:7.68e-5 (favourable)	Tissue enriched	Tissue enhanced		spleen: 151.8	breast: 39.6	Cell line enriched	16	HEL: 105.6
REEP2	C5orf19, SGC32445, SPG72, Yip2d	ENSG00000132563	Receptor accessory protein 2	5	138439017-138446969	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA031813	Enhanced				Breast cancer:7.83e-5 (favourable), Glioma:3.43e-4 (unfavourable), Melanoma:9.31e-4 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 90.1	smooth muscle: 18.0	Cell line enhanced		AN3-CA: 89.1;SCLC-21H: 46.8;SH-SY5Y: 47.6
RPL27A	L27A	ENSG00000166441	Ribosomal protein L27a	11	8682411-8714759	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA060776, HPA063379	Supported		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:2.83e-10 (unfavourable), Breast cancer:7.84e-5 (favourable)	Expressed in all	Expressed in all			lymph node: 2813.8	Expressed in all		
CHGA		ENSG00000100604	Chromogranin A	14	92923080-92935293	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000023, HPA017369, CAB040544, CAB055506, CAB058688	Enhanced		Supported	Vesicles	Breast cancer:7.85e-5 (favourable), Liver cancer:2.40e-4 (unfavourable), Urothelial cancer:3.99e-4 (unfavourable), Pancreatic cancer:4.07e-4 (favourable)	Tissue enhanced	Tissue enriched	9	parathyroid gland: 7061.6	adrenal gland: 818.1	Group enriched	156	SCLC-21H: 285.4;SH-SY5Y: 700.4
DOK7	C4orf25, Dok-7, FLJ33718, FLJ39137	ENSG00000175920	Docking protein 7	4	3463311-3494483	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA059449, HPA062780	Approved		Supported	Nucleoplasm<br>Mitochondria	Breast cancer:8.45e-5 (favourable), Urothelial cancer:1.28e-4 (favourable), Endometrial cancer:2.19e-4 (favourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 6.7;heart muscle: 11.1	skeletal muscle: 4.7	Cell line enhanced		MCF7: 27.3;RH-30: 6.5;T-47d: 7.4
CD79A	IGA, MB-1	ENSG00000105369	CD79a molecule	19	41877120-41881372	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000019	Enhanced				Head and neck cancer:1.18e-5 (favourable), Renal cancer:2.15e-5 (unfavourable), Breast cancer:8.45e-5 (favourable)	Mixed	Group enriched	6	appendix: 263.8;lymph node: 515.1;spleen: 317.9;tonsil: 423.1	stomach: 63.3	Group enriched	23	Daudi: 1084.6;REH: 432.6;U-698: 905.8
NDUFA5	B13, CI-13kB, CI-13KD-B, NUFM, UQOR13	ENSG00000128609	NADH:ubiquinone oxidoreductase subunit A5	7	123536997-123558255	Predicted intracellular proteins	Evidence at protein level	HPA043175	Supported				Renal cancer:3.99e-9 (favourable), Breast cancer:8.47e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 250.6	Expressed in all		
PSME1	IFI5111, PA28alpha	ENSG00000092010	Proteasome activator subunit 1	14	24136158-24138967	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006632	Approved				Breast cancer:8.87e-5 (favourable), Thyroid cancer:4.60e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 329.6	Expressed in all		
ZBED6CL	C7orf29	ENSG00000188707	ZBED6 C-terminal like	7	150329789-150332721	Predicted intracellular proteins	Evidence at transcript level	HPA019724, HPA055805	Approved		Approved	Nuclear membrane<br>Vesicles	Renal cancer:1.38e-5 (unfavourable), Pancreatic cancer:2.44e-5 (favourable), Glioma:5.65e-5 (unfavourable), Breast cancer:9.48e-5 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 31.7;parathyroid gland: 30.4	lymph node: 9.8	Cell line enhanced		HDLM-2: 80.9;K-562: 33.8
SFPQ	PPP1R140, PSF	ENSG00000116560	Splicing factor proline and glutamine rich	1	35176378-35193148	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009886, HPA047513, HPA054689	Enhanced		Enhanced	Nucleoplasm	Liver cancer:7.91e-13 (unfavourable), Breast cancer:9.56e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 135.5	Expressed in all		
ZNF586	FLJ20070	ENSG00000083828	Zinc finger protein 586	19	57769655-57819939	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030306, HPA060782	Approved		Approved	Nucleoli fibrillar center<br>Vesicles	Breast cancer:9.83e-5 (favourable), Urothelial cancer:5.36e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 16.3	Mixed		
GSTM4		ENSG00000168765	Glutathione S-transferase mu 4	1	109656081-109674836	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048652, HPA055972, HPA055973	Approved		Approved	Cytokinetic bridge<br>Cytosol	Breast cancer:9.96e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 149.7	Mixed		
BTN2A2	BT2.2, BTF2, BTN2.2	ENSG00000124508	Butyrophilin subfamily 2 member A2	6	26383096-26394874	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051504	Uncertain		Supported	Mitochondria	Breast cancer:1.01e-4 (favourable)	Expressed in all	Mixed			lymph node: 37.6	Mixed		
GNAI2	GIP, GNAI2B	ENSG00000114353	G protein subunit alpha i2	3	50226292-50259355	Predicted intracellular proteins	Evidence at protein level	HPA007704	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Breast cancer:1.03e-4 (favourable)	Expressed in all	Expressed in all			placenta: 330.6	Expressed in all		
MRPL16	FLJ20484, PNAS-111	ENSG00000166902	Mitochondrial ribosomal protein L16	11	59806135-59810872	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA054133	Supported				Breast cancer:1.04e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 71.6	Expressed in all		
CYP27A1	CP27, CTX, CYP27	ENSG00000135929	Cytochrome P450 family 27 subfamily A member 1	2	218781749-218815293	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA059155	Enhanced		Enhanced	Mitochondria	Liver cancer:8.62e-6 (favourable), Breast cancer:1.05e-4 (favourable)	Expressed in all	Tissue enhanced		liver: 279.5	lung: 98.4	Cell line enhanced		Hep G2: 187.0;RPTEC TERT1: 50.8;SK-MEL-30: 86.7;WM-115: 42.3
CD74	DHLAG	ENSG00000019582	CD74 molecule	5	150401637-150412929	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB002506, HPA010592	Enhanced		Supported	Golgi apparatus	Endometrial cancer:6.53e-6 (favourable), Breast cancer:1.06e-4 (favourable)	Expressed in all	Expressed in all			spleen: 6545.9	Cell line enhanced		CAPAN-2: 1796.9;Daudi: 2297.1;HDLM-2: 4315.9;REH: 2549.8
TP63	EEC3, KET, NBP, OFC8, p51, p53CP, p63, p73H, p73L, SHFM4, TP53CP, TP53L, TP73L	ENSG00000073282	Tumor protein p63	3	189631416-189897279	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000083, HPA006288, HPA007010	Enhanced		Enhanced	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Breast cancer:1.07e-4 (favourable)	Group enriched	Tissue enhanced		esophagus: 60.9;skin: 164.1	urinary bladder: 28.8	Group enriched	5	HaCaT: 77.1;HBEC3-KT: 119.9;hTCEpi: 89.8;hTERT-HME1: 90.5;RT4: 147.6
BTBD6	BDPL	ENSG00000184887	BTB domain containing 6	14	105248490-105251093	Predicted intracellular proteins	Evidence at protein level	HPA031355	Approved		Approved	Nucleoplasm	Renal cancer:6.51e-5 (favourable), Breast cancer:1.11e-4 (favourable), Pancreatic cancer:2.25e-4 (favourable)	Expressed in all	Expressed in all			testis: 73.4	Mixed		
MORN3		ENSG00000139714	MORN repeat containing 3	12	121648742-121672631	Predicted intracellular proteins	Evidence at protein level	HPA038709, HPA038710	Uncertain		Approved	Nucleoplasm	Breast cancer:1.16e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 6.7	testis: 5.1	Group enriched	7	BEWO: 14.7;CACO-2: 7.0
SIAH2		ENSG00000181788	Siah E3 ubiquitin protein ligase 2	3	150741127-150763477	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA061293, CAB069930	Approved		Supported	Nucleoplasm<br>Vesicles	Pancreatic cancer:8.21e-5 (unfavourable), Breast cancer:1.17e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 95.3	Expressed in all		
ACYP1		ENSG00000119640	Acylphosphatase 1	14	75053221-75069483	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA034944	Approved		Approved	Nucleus<br>Cytosol	Liver cancer:6.14e-7 (unfavourable), Breast cancer:1.17e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 46.4	Expressed in all		
TSPYL5	KIAA1750	ENSG00000180543	TSPY like 5	8	97273474-97277964	Predicted intracellular proteins	Evidence at protein level	HPA031347	Enhanced		Approved	Golgi apparatus<br>Cytosol	Renal cancer:1.40e-5 (favourable), Breast cancer:1.21e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 81.4	ovary: 30.4	Cell line enhanced		SCLC-21H: 70.7;SH-SY5Y: 49.4
IP6K2	IHPK2	ENSG00000068745	Inositol hexakisphosphate kinase 2	3	48688003-48740353	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007532, HPA070811	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cell Junctions	Breast cancer:1.25e-4 (favourable), Urothelial cancer:1.83e-4 (favourable), Lung cancer:2.95e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 131.1	Expressed in all		
PSME2	PA28beta	ENSG00000100911	Proteasome activator subunit 2	14	24143362-24147570	Predicted intracellular proteins	Evidence at protein level	HPA062661			Approved	Nucleus	Renal cancer:3.47e-5 (unfavourable), Breast cancer:1.27e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 287.9	Expressed in all		
SEMA3B	LUCA-1, SemA, sema5, SEMAA, semaV	ENSG00000012171	Semaphorin 3B	3	50267558-50277546	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030651	Approved				Breast cancer:1.27e-4 (favourable)	Expressed in all	Mixed			adrenal gland: 75.5	Cell line enhanced		Hep G2: 74.9;WM-115: 171.7
KRT5	EBS2, KRT5A	ENSG00000186081	Keratin 5	12	52514575-52520687	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000027, CAB000129, HPA059479	Enhanced		Supported	Intermediate filaments	Breast cancer:1.27e-4 (favourable)	Tissue enhanced	Group enriched	9	esophagus: 3256.1;skin: 5996.8	tonsil: 516.9	Group enriched	6	HaCaT: 2557.9;HBEC3-KT: 3723.5;hTCEpi: 8392.0
KLHDC7B	MGC16635	ENSG00000130487	Kelch domain containing 7B	22	50548033-50551023	Predicted intracellular proteins	Evidence at protein level	HPA000518	Uncertain				Breast cancer:1.30e-4 (favourable)	Tissue enhanced	Tissue enhanced		parathyroid gland: 12.7	thyroid gland: 3.4	Group enriched	6	HHSteC: 18.6;HMC-1: 87.0
CDON	CDO, CDON1, ORCAM	ENSG00000064309	Cell adhesion associated, oncogene regulated	11	125955796-126063335	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB012422, HPA017377	Uncertain				Renal cancer:1.78e-7 (unfavourable), Breast cancer:1.35e-4 (favourable)	Mixed	Tissue enhanced		thyroid gland: 75.5	ovary: 53.5	Cell line enhanced		AF22: 55.0;ASC diff: 47.4;RH-30: 93.1
COL17A1	BP180, BPAG2	ENSG00000065618	Collagen type XVII alpha 1 chain	10	104031286-104086002	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043673, HPA052963	Enhanced		Supported	Golgi apparatus<br>Plasma membrane	Breast cancer:1.38e-4 (favourable), Pancreatic cancer:1.86e-4 (unfavourable)	Tissue enhanced	Tissue enriched	14	skin: 769.3	placenta: 53.1	Group enriched	6	CAPAN-2: 175.9;HaCaT: 403.2;HBEC3-KT: 525.2;hTCEpi: 673.0;hTERT-HME1: 604.3
SPN	CD43, GPL115, LSN	ENSG00000197471	Sialophorin	16	29662979-29670876	CD markers, Predicted membrane proteins	Evidence at protein level	CAB002666, HPA055244	Enhanced		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cell Junctions	Endometrial cancer:3.08e-5 (favourable), Breast cancer:1.40e-4 (favourable), Melanoma:1.88e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 38.6;lung: 33.3	lymph node: 25.4	Cell line enhanced		HEL: 209.9;HL-60: 167.0;HMC-1: 98.8;U-937: 115.3
RNF150	KIAA1214	ENSG00000170153	Ring finger protein 150	4	140859807-141212877	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA037987	Uncertain				Breast cancer:1.41e-4 (favourable)	Mixed	Mixed			endometrium,fallopian tube: 21.3	Cell line enhanced		fHDF/TERT166: 21.9;SH-SY5Y: 42.3
DHRS12	FLJ13639, SDR40C1	ENSG00000102796	Dehydrogenase/reductase 12	13	51767993-51804157	Predicted intracellular proteins	Evidence at protein level	CAB034238, HPA057028, HPA058315	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:2.22e-16 (favourable), Breast cancer:1.41e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 22.0	Mixed		
IFI35	IFP35	ENSG00000068079	Interferon induced protein 35	17	43006725-43014456	Predicted intracellular proteins	Evidence at protein level	HPA045946			Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.03e-5 (unfavourable), Breast cancer:1.41e-4 (favourable)	Expressed in all	Expressed in all			spleen: 44.0	Cell line enhanced		BJ hTERT+ SV40 Large T+: 190.3;BJ hTERT+ SV40 Large T+ RasG12V: 291.3
QARS		ENSG00000172053	Glutaminyl-tRNA synthetase	3	49095932-49105135	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036986, HPA036987	Enhanced		Enhanced	Cytosol	Renal cancer:5.60e-6 (favourable), Breast cancer:1.43e-4 (favourable)	Expressed in all	Expressed in all			rectum: 117.0	Expressed in all		
RFX3		ENSG00000080298	Regulatory factor X3	9	3218297-3526004	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035689	Enhanced		Approved	Nucleoplasm<br>Vesicles	Breast cancer:1.47e-4 (favourable)	Mixed	Tissue enhanced		testis: 38.6	fallopian tube: 18.3	Cell line enhanced		AF22: 26.0;SCLC-21H: 16.6
TTC39C	C18orf17, FLJ33761, HsT2697	ENSG00000168234	Tetratricopeptide repeat domain 39C	18	23992773-24135610	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA065705, HPA065713	Approved		Approved	Nucleoplasm	Renal cancer:2.60e-5 (unfavourable), Breast cancer:1.48e-4 (favourable)	Expressed in all	Expressed in all			liver: 47.8	Mixed		
OSGEP	GCPL1, KAE1, OSGEP1, PRSMG1	ENSG00000092094	O-sialoglycoprotein endopeptidase	14	20446411-20455105	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039751	Uncertain		Supported	Nucleoplasm<br>Plasma membrane	Renal cancer:4.64e-6 (unfavourable), Breast cancer:1.48e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 12.7	Expressed in all		
RPS24	S24	ENSG00000138326	Ribosomal protein S24	10	78033760-78056812	Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA003364	Approved		Approved	Nuclear bodies<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:1.10e-10 (unfavourable), Breast cancer:1.50e-4 (favourable)	Expressed in all	Expressed in all			ovary: 6825.3	Expressed in all		
DRC3	CFAP134, DKFZP586M1120, LRRC48	ENSG00000171962	Dynein regulatory complex subunit 3	17	17972813-18016889	Predicted intracellular proteins	Evidence at transcript level	HPA036040, HPA036041	Approved				Endometrial cancer:4.05e-5 (favourable), Breast cancer:1.51e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 99.2	testis: 21.8	Mixed		
RELB	REL-B	ENSG00000104856	RELB proto-oncogene, NF-kB subunit	19	45001430-45038198	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB007753, HPA040506	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.99e-6 (unfavourable), Breast cancer:1.55e-4 (favourable)	Expressed in all	Expressed in all			appendix: 25.1	Cell line enhanced		HDLM-2: 73.5
UBA7	D8, UBA1B, UBE1L, UBE2	ENSG00000182179	Ubiquitin like modifier activating enzyme 7	3	49805207-49813946	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB015444, HPA058182	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:1.04e-5 (unfavourable), Urothelial cancer:1.48e-4 (favourable), Breast cancer:1.55e-4 (favourable)	Expressed in all	Expressed in all			spleen: 65.5	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 55.3;HMC-1: 91.3
TRIM45	FLJ13181, RNF99	ENSG00000134253	Tripartite motif containing 45	1	117111060-117122587	Predicted intracellular proteins	Evidence at protein level	HPA030266, HPA054308	Uncertain		Supported	Cytokinetic bridge<br>Cytosol	Breast cancer:1.58e-4 (favourable), Thyroid cancer:2.92e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 14.4	Cell line enhanced		RH-30: 30.6
C1orf53		ENSG00000203724	Chromosome 1 open reading frame 53	1	197902647-197907367	Predicted intracellular proteins	Evidence at protein level	HPA065352			Approved	Vesicles<br>Aggresome	Breast cancer:1.63e-4 (favourable), Endometrial cancer:3.78e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 6.2	Mixed		
OMA1	FLJ33782, MPRP-1, YKR087C, ZMPOMA1	ENSG00000162600	OMA1 zinc metallopeptidase	1	58415384-58546802	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055120	Approved		Approved	Nucleoplasm<br>Mitochondria	Breast cancer:1.63e-4 (favourable), Colorectal cancer:7.70e-4 (favourable), Lung cancer:8.52e-4 (favourable)	Expressed in all	Expressed in all			prostate: 31.9	Expressed in all		
FBL	FIB, FLRN, RNU3IP1	ENSG00000105202	Fibrillarin	19	39834458-39846414	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001514, HPA049546	Supported		Enhanced	Nucleoli fibrillar center	Renal cancer:4.52e-6 (unfavourable), Liver cancer:1.32e-4 (unfavourable), Breast cancer:1.65e-4 (favourable)	Expressed in all	Expressed in all			ovary: 212.6	Expressed in all		
POU2AF1	BOB1, OBF1	ENSG00000110777	POU class 2 associating factor 1	11	111352252-111455630	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011193	Enhanced				Cervical cancer:1.63e-4 (favourable), Breast cancer:1.68e-4 (favourable), Head and neck cancer:3.59e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 101.7;tonsil: 93.7	appendix: 55.5	Cell line enhanced		Daudi: 190.2;Karpas-707: 212.1;U-266/70: 217.7;U-698: 374.3
CD3E		ENSG00000198851	CD3e molecule	11	118304545-118316175	CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB000010, HPA040957, HPA043955, CAB072863, CAB072864	Enhanced				Endometrial cancer:2.30e-6 (favourable), Renal cancer:1.12e-5 (unfavourable), Melanoma:1.18e-4 (favourable), Head and neck cancer:1.32e-4 (favourable), Cervical cancer:1.62e-4 (favourable), Breast cancer:1.72e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 200.5;tonsil: 113.4	spleen: 95.0	Cell line enriched	92	MOLT-4: 531.3
HSPA2		ENSG00000126803	Heat shock protein family A (Hsp70) member 2	14	64535905-64546173	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000798, HPA052504	Enhanced	Approved	Approved	Nucleoplasm<br>Vesicles	Breast cancer:1.78e-4 (favourable), Lung cancer:9.11e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 188.6	cerebral cortex: 96.4	Cell line enhanced		A549: 67.9;BEWO: 110.2;BJ hTERT+: 80.5;SCLC-21H: 119.3
HPDL	4-HPPD-L, GLOXD1, MGC15668	ENSG00000186603	4-hydroxyphenylpyruvate dioxygenase like	1	45326905-45328533	Predicted intracellular proteins	Evidence at protein level	HPA031997, HPA057346	Approved		Supported	Mitochondria	Endometrial cancer:1.60e-5 (unfavourable), Ovarian cancer:1.03e-4 (favourable), Breast cancer:1.81e-4 (favourable)	Mixed	Mixed			colon: 3.8	Cell line enhanced		BEWO: 118.1;SK-BR-3: 58.4
EGR3	PILOT	ENSG00000179388	Early growth response 3	8	22687659-22693302	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA006206, CAB009373	Uncertain		Uncertain	Nucleus<br>Vesicles	Breast cancer:1.83e-4 (favourable), Melanoma:4.78e-4 (favourable)	Mixed	Mixed			gallbladder: 49.6	Cell line enhanced		HMC-1: 8.5;MCF7: 25.2;SK-MEL-30: 17.0
MFSD6L	FLJ35773	ENSG00000185156	Major facilitator superfamily domain containing 6 like	17	8797162-8799349	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA023164	Uncertain				Breast cancer:1.84e-4 (favourable)	Mixed	Tissue enhanced		testis: 29.8	parathyroid gland: 8.4	Cell line enriched	5	HMC-1: 7.5
MAGOH	MAGOH1, MAGOHA	ENSG00000162385	Mago homolog, exon junction complex core component	1	53226892-53238610	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB015425, HPA043036, HPA047754	Approved		Supported	Nucleus	Renal cancer:1.45e-5 (unfavourable), Breast cancer:1.85e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 82.2	Expressed in all		
TRIM17	RBCC, RNF16, terf	ENSG00000162931	Tripartite motif containing 17	1	228407940-228416861	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA054908	Uncertain		Approved	Vesicles	Breast cancer:1.86e-4 (favourable)	Mixed	Tissue enhanced		testis: 27.8	cerebral cortex: 6.1	Cell line enhanced		BEWO: 8.7;SH-SY5Y: 5.0;T-47d: 10.6
TCN1	TC1, TCI	ENSG00000134827	Transcobalamin 1	11	59852800-59866575	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.56e-8 (unfavourable), Breast cancer:1.90e-4 (favourable)	Tissue enhanced	Tissue enhanced		bone marrow: 123.8;gallbladder: 254.4;salivary gland: 315.5	stomach: 75.5	Cell line enhanced		CAPAN-2: 4.7;HaCaT: 4.6;PC-3: 6.4;SiHa: 7.7
CD6	Tp120	ENSG00000013725	CD6 molecule	11	60971680-61020377	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002489, CAB016252	Enhanced				Head and neck cancer:5.10e-6 (favourable), Cervical cancer:1.57e-5 (favourable), Renal cancer:1.82e-4 (unfavourable), Breast cancer:1.95e-4 (favourable), Endometrial cancer:2.41e-4 (favourable)	Mixed	Tissue enhanced		appendix: 28.5;lymph node: 49.2	tonsil: 26.8	Cell line enriched	17	MOLT-4: 31.3
PLEKHA4	PEPP1	ENSG00000105559	Pleckstrin homology domain containing A4	19	48837097-48868632	Predicted intracellular proteins	Evidence at protein level	HPA042978, HPA048473	Uncertain		Approved	Plasma membrane<br>Cytokinetic bridge<br>Centrosome<br>Cytosol	Breast cancer:1.97e-4 (favourable), Liver cancer:8.68e-4 (unfavourable)	Expressed in all	Mixed			ovary: 22.3	Cell line enhanced		AN3-CA: 58.6;BJ hTERT+ SV40 Large T+ RasG12V: 48.0;SK-MEL-30: 57.7
TAPBPL	FLJ10143, TAPBP-R, TAPBPR	ENSG00000139192	TAP binding protein like	12	6451690-6466517	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039545	Uncertain				Renal cancer:6.04e-5 (favourable), Breast cancer:1.98e-4 (favourable), Urothelial cancer:7.86e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.2	Cell line enhanced		CAPAN-2: 58.5
SH2D1A	DSHP, EBVS, IMD5, LYP, MTCP1, SAP, XLP, XLPD	ENSG00000183918	SH2 domain containing 1A	X	124227868-124373197	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.94e-6 (unfavourable), Breast cancer:2.03e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 36.3;spleen: 17.5	tonsil: 13.2	Group enriched	6	HDLM-2: 89.9;Karpas-707: 148.7;MOLT-4: 209.2
PHGR1		ENSG00000233041	Proline, histidine and glycine rich 1	15	40351033-40356434	Predicted intracellular proteins	Evidence at protein level	HPA068787	Enhanced		Approved	Vesicles	Breast cancer:2.05e-4 (favourable)	Group enriched	Group enriched	7	colon: 1448.4;duodenum: 892.1;rectum: 399.5;small intestine: 1777.5	stomach: 166.8	Cell line enhanced		BEWO: 12.3;HaCaT: 16.0;SCLC-21H: 72.5
ARHGAP26	GRAF, KIAA0621, OPHN1L, OPHN1L1	ENSG00000145819	Rho GTPase activating protein 26	5	142770384-143229011	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035106, HPA035107	Enhanced		Approved	Cytosol	Urothelial cancer:2.88e-6 (favourable), Endometrial cancer:5.93e-6 (favourable), Cervical cancer:1.36e-4 (favourable), Breast cancer:2.05e-4 (favourable), Colorectal cancer:6.95e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 30.8	Cell line enhanced		Karpas-707: 61.5
TTC22	FLJ20619	ENSG00000006555	Tetratricopeptide repeat domain 22	1	54779712-54801267	Predicted intracellular proteins	Evidence at protein level	HPA035072	Uncertain				Breast cancer:2.06e-4 (favourable), Liver cancer:7.73e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 40.6	skin: 22.7	Cell line enhanced		A-431: 7.9;CAPAN-2: 9.5;HaCaT: 11.0;hTCEpi: 5.0;RPMI-8226: 5.6
MIA	CD-RAP	ENSG00000261857	Melanoma inhibitory activity	19	40771648-40777490	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA031950, HPA042369	Supported	Supported			Breast cancer:2.08e-4 (favourable)	Tissue enriched	Tissue enhanced		breast: 62.9;stomach: 50.0	salivary gland: 18.4	Group enriched	41	AN3-CA: 79.3;CAPAN-2: 63.4;SK-MEL-30: 198.0;WM-115: 233.6
CASP7	CMH-1, ICE-LAP3, MCH3	ENSG00000165806	Caspase 7	10	113679162-113730907	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB025563	Approved				Breast cancer:2.11e-4 (favourable), Renal cancer:5.90e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 74.4	Mixed		
FBXO27	Fbg5, Fbx27	ENSG00000161243	F-box protein 27	19	38990714-39032785	Predicted intracellular proteins	Evidence at protein level	HPA046800, HPA062242	Approved		Approved	Nucleoplasm	Endometrial cancer:3.53e-5 (unfavourable), Breast cancer:2.15e-4 (favourable), Glioma:7.83e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 22.7	esophagus: 8.4	Cell line enhanced		RT4: 14.1
CBR1	CBR, SDR21C1	ENSG00000159228	Carbonyl reductase 1	21	36069941-36073166	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018433	Approved		Approved	Nucleus<br>Cytosol	Breast cancer:2.18e-4 (favourable), Renal cancer:4.75e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 544.9	Mixed		
REC8	kleisin-alpha, REC8L1, Rec8p	ENSG00000100918	REC8 meiotic recombination protein	14	24171853-24180257	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031727, HPA031729	Approved		Approved	Nucleoplasm	Renal cancer:1.41e-7 (unfavourable), Breast cancer:2.19e-4 (favourable), Pancreatic cancer:5.57e-4 (favourable)	Expressed in all	Tissue enhanced		fallopian tube: 37.4	testis: 28.9	Cell line enhanced		AF22: 20.6;MOLT-4: 18.0;SH-SY5Y: 98.0
ZNF671	FLJ23506	ENSG00000083814	Zinc finger protein 671	19	57719751-57727624	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046099	Uncertain		Approved	Nucleoplasm	Breast cancer:2.20e-4 (favourable), Pancreatic cancer:3.57e-4 (favourable)	Mixed	Mixed			parathyroid gland: 16.6	Mixed		
TMEM69	C1orf154, FLJ21029	ENSG00000159596	Transmembrane protein 69	1	45687214-45694443	Predicted membrane proteins	Evidence at transcript level	HPA026993	Approved		Approved	Nucleoplasm	Liver cancer:3.66e-8 (unfavourable), Breast cancer:2.24e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.9	Expressed in all		
POLR1E	FLJ13390, FLJ13970, PAF53, PRAF1	ENSG00000137054	RNA polymerase I subunit E	9	37485935-37503697	Predicted intracellular proteins, Predicted membrane proteins, RNA polymerase related proteins	Evidence at protein level	HPA022527, HPA052400	Supported		Supported	Nucleus<br>Nucleoli fibrillar center	Breast cancer:2.27e-4 (favourable)	Expressed in all	Expressed in all			ovary: 51.5	Expressed in all		
ENOSF1	HSRTSBETA, rTS, TYMSAS	ENSG00000132199	Enolase superfamily member 1	18	670324-712676	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047829	Enhanced				Breast cancer:2.27e-4 (favourable)	Expressed in all	Mixed			kidney: 38.9	Expressed in all		
PRSS2	TRY2	ENSG00000275896	Protease, serine 2	7	142760398-142774564	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA062452, HPA063471	Supported		Approved	Endoplasmic reticulum<br>Vesicles	Breast cancer:2.32e-4 (favourable)	Tissue enriched	Tissue enriched	53	pancreas: 30215.4	small intestine: 567.7	Group enriched	6	RPMI-8226: 46.1;U-2 OS: 14.3
SCUBE2	Cegb1, Cegf1, FLJ16792	ENSG00000175356	Signal peptide, CUB domain and EGF like domain containing 2	11	9020391-9138114	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA006353, HPA029871	Uncertain				Breast cancer:2.41e-4 (favourable)	Expressed in all	Mixed			epididymis: 63.1	Cell line enhanced		HAP1: 6.0;SK-MEL-30: 6.6;T-47d: 26.8
ADPRH	ARH1	ENSG00000144843	ADP-ribosylarginine hydrolase	3	119579268-119589945	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB001701, HPA036961	Approved		Approved	Nucleus<br>Nuclear membrane	Breast cancer:2.42e-4 (favourable)	Expressed in all	Mixed			lung: 20.1	Cell line enhanced		HDLM-2: 22.2;HMC-1: 16.3;Karpas-707: 18.2;U-266/70: 18.7
RGS2	G0S8	ENSG00000116741	Regulator of G-protein signaling 2	1	192809039-192812283	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA013385			Approved	Cytosol	Renal cancer:2.90e-5 (unfavourable), Breast cancer:2.43e-4 (favourable), Stomach cancer:3.56e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 749.0	Cell line enhanced		hTCEpi: 101.7;PC-3: 208.8
U2AF1L4	MGC33901, U2AF1L3, U2af26	ENSG00000161265	U2 small nuclear RNA auxiliary factor 1 like 4	19	35742464-35745445	Predicted intracellular proteins	Evidence at protein level	HPA052083, HPA061644	Supported		Approved	Nucleoplasm	Head and neck cancer:2.58e-5 (favourable), Pancreatic cancer:8.58e-5 (favourable), Renal cancer:9.73e-5 (unfavourable), Breast cancer:2.44e-4 (favourable), Urothelial cancer:7.05e-4 (favourable)	Expressed in all	Mixed			testis: 7.7	Mixed		
TNFAIP8	GG2-1, MDC-3.13, SCC-S2	ENSG00000145779	TNF alpha induced protein 8	5	119268692-119399688	Predicted intracellular proteins	Evidence at protein level	HPA054434, HPA057089	Uncertain		Approved	Nucleoplasm	Breast cancer:2.45e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 134.4	Expressed in all		
LAMTOR4	C7orf59	ENSG00000188186	Late endosomal/lysosomal adaptor, MAPK and MTOR activator 4	7	100148907-100155944	Predicted intracellular proteins	Evidence at protein level	HPA020998	Enhanced		Enhanced	Vesicles	Breast cancer:2.48e-4 (favourable), Cervical cancer:6.08e-4 (favourable)	Expressed in all	Expressed in all			skin: 314.5	Expressed in all		
FABP7	B-FABP, BLBP	ENSG00000164434	Fatty acid binding protein 7	6	122779475-122784074	Predicted intracellular proteins	Evidence at protein level	CAB025488, HPA028825, CAB058697	Enhanced				Renal cancer:1.65e-6 (unfavourable), Breast cancer:2.49e-4 (favourable)	Group enriched	Group enriched	13	breast: 33.1;cerebral cortex: 102.3	skin: 5.2	Group enriched	8	AF22: 75.1;U-251 MG: 17.6;WM-115: 45.7
RPL11	L11	ENSG00000142676	Ribosomal protein L11	1	23691779-23696425	Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA002734, HPA074839	Approved		Approved	Vesicles	Renal cancer:5.93e-6 (unfavourable), Breast cancer:2.55e-4 (favourable)	Expressed in all	Expressed in all			ovary: 4915.9	Expressed in all		
RAB27A	GS2, HsT18676, RAB27, RAM	ENSG00000069974	RAB27A, member RAS oncogene family	15	55202966-55319113	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001333, CAB034046	Enhanced				Renal cancer:1.67e-4 (unfavourable), Breast cancer:2.56e-4 (favourable)	Expressed in all	Mixed			stomach: 115.1	Cell line enhanced		K-562: 212.3
HNRNPA1L2	LOC144983	ENSG00000139675	Heterogeneous nuclear ribonucleoprotein A1-like 2	13	52640786-52643796	Predicted intracellular proteins	Evidence at protein level						Breast cancer:2.58e-4 (favourable), Pancreatic cancer:4.26e-4 (favourable)	Expressed in all	Mixed			ovary: 6.0	Expressed in all		
SH3D21	C1orf113, FLJ22938	ENSG00000214193	SH3 domain containing 21	1	36306387-36324886	Predicted intracellular proteins	Evidence at protein level	HPA042212, HPA042456, HPA066168	Approved		Approved	Nucleus<br>Plasma membrane	Renal cancer:1.76e-6 (unfavourable), Breast cancer:2.60e-4 (favourable)	Mixed	Tissue enhanced		small intestine: 22.2	skin: 15.5	Cell line enhanced		HaCaT: 15.2
C1orf226	FLJ13137	ENSG00000239887	Chromosome 1 open reading frame 226	1	162366908-162386818	Predicted intracellular proteins	Evidence at protein level	HPA052251	Approved		Approved	Nucleoplasm	Renal cancer:4.44e-5 (favourable), Urothelial cancer:1.13e-4 (favourable), Breast cancer:2.60e-4 (favourable)	Expressed in all	Mixed			adrenal gland: 12.7	Cell line enhanced		HEL: 20.8
EEF1B2		ENSG00000114942	Eukaryotic translation elongation factor 1 beta 2	2	206159585-206162928	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012477, HPA035029	Supported		Approved	Nucleoli fibrillar center<br>Cytosol	Renal cancer:3.62e-6 (unfavourable), Breast cancer:2.60e-4 (favourable), Melanoma:9.95e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 515.5	Expressed in all		
KRT14	EBS3, EBS4	ENSG00000186847	Keratin 14	17	41582279-41586921	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000134, HPA000452, HPA000539, HPA023040	Enhanced		Enhanced	Intermediate filaments	Breast cancer:2.66e-4 (favourable)	Group enriched	Tissue enriched	19	skin: 7943.3	breast: 421.8	Cell line enhanced		HaCaT: 3480.4;HBEC3-KT: 1395.9;hTCEpi: 1722.3;U-2197: 628.5
RPS29	S29	ENSG00000213741	Ribosomal protein S29	14	49570984-49599164	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA004107	Approved		Supported	Endoplasmic reticulum<br>Cytosol	Breast cancer:2.66e-4 (favourable)	Expressed in all	Expressed in all			breast: 3653.3	Expressed in all		
TAPBP	TAPA	ENSG00000231925	TAP binding protein	6	33299694-33314387	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007066	Approved				Breast cancer:2.76e-4 (favourable), Melanoma:6.29e-4 (favourable)	Expressed in all	Expressed in all			spleen: 30.7	Cell line enhanced		CAPAN-2: 67.6
PMPCB	MPPB, MPPP52	ENSG00000105819	Peptidase, mitochondrial processing beta subunit	7	103297422-103329511	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040674, HPA074168	Approved		Supported	Mitochondria	Renal cancer:2.95e-8 (favourable), Breast cancer:2.79e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 70.0	Expressed in all		
SORBS1	CAP, FLJ12406, KIAA1296, ponsin, SH3D5, sh3p12	ENSG00000095637	Sorbin and SH3 domain containing 1	10	95311771-95561414	Predicted intracellular proteins	Evidence at protein level	HPA027559, HPA043084	Enhanced		Supported	Plasma membrane<br>Focal adhesion sites<br>Centrosome	Breast cancer:2.84e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 320.1	Cell line enhanced		CACO-2: 21.9;HMC-1: 39.4;SK-MEL-30: 30.9
INO80B	hIes2, HMGA1L4, HMGIYL4, IES2, PAP-1BP, PAPA-1, ZNHIT4	ENSG00000115274	INO80 complex subunit B	2	74455023-74457960	Predicted intracellular proteins	Evidence at protein level	HPA070644			Supported	Nucleus<br>Nucleoli	Renal cancer:1.56e-5 (unfavourable), Breast cancer:2.89e-4 (favourable), Stomach cancer:8.44e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 42.2	Expressed in all		
CCDC28B	MGC1203, RP4-622L5.5	ENSG00000160050	Coiled-coil domain containing 28B	1	32200386-32205387	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028589	Uncertain				Pancreatic cancer:1.10e-5 (favourable), Breast cancer:2.92e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 40.8	testis: 22.7	Mixed		
POLR3GL	flj32422, MGC3200	ENSG00000121851	RNA polymerase III subunit G like	1	145964702-145978848	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA027288	Uncertain				Endometrial cancer:6.52e-5 (favourable), Breast cancer:2.96e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 59.5	Expressed in all		
ACAA1		ENSG00000060971	Acetyl-CoA acyltransferase 1	3	38103129-38137242	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006764, HPA007244	Enhanced		Enhanced	Peroxisomes	Renal cancer:6.99e-9 (favourable), Head and neck cancer:1.23e-4 (favourable), Breast cancer:3.00e-4 (favourable), Endometrial cancer:7.53e-4 (favourable)	Expressed in all	Expressed in all			liver: 328.4	Expressed in all		
CD3D	T3D	ENSG00000167286	CD3d molecule	11	118338954-118342744	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013055	Enhanced				Endometrial cancer:1.73e-7 (favourable), Renal cancer:3.07e-5 (unfavourable), Cervical cancer:8.46e-5 (favourable), Head and neck cancer:1.70e-4 (favourable), Breast cancer:3.00e-4 (favourable), Urothelial cancer:6.16e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 199.3;tonsil: 119.1	appendix: 86.9	Cell line enriched	7	MOLT-4: 903.0
MZT2A	FAM128A, MOZART2A	ENSG00000173272	Mitotic spindle organizing protein 2A	2	131464900-131492743	Predicted intracellular proteins	Evidence at protein level	HPA051758, HPA052623	Approved		Supported	Centrosome<br>Cytosol	Renal cancer:3.04e-11 (unfavourable), Breast cancer:3.04e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 40.5	Mixed		
SEC14L2	C22orf6, KIAA1186, KIAA1658, SPF, TAP, TAP1	ENSG00000100003	SEC14 like lipid binding 2	22	30396857-30425317	Predicted intracellular proteins	Evidence at protein level	HPA064466	Approved		Supported	Nucleus<br>Cytosol	Head and neck cancer:7.63e-6 (unfavourable), Breast cancer:3.05e-4 (favourable)	Expressed in all	Tissue enhanced		epididymis: 104.9;liver: 125.6;prostate: 83.0	breast: 57.3	Cell line enhanced		HBEC3-KT: 61.6
CTSW		ENSG00000172543	Cathepsin W	11	65879809-65883741	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB016345	Enhanced				Endometrial cancer:8.36e-6 (favourable), Renal cancer:8.84e-6 (unfavourable), Breast cancer:3.06e-4 (favourable), Head and neck cancer:9.89e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 70.6;spleen: 60.4	lung: 36.5	Group enriched	20	HEL: 149.5;NB-4: 242.5
TMEM60	C7orf35, DC32	ENSG00000135211	Transmembrane protein 60	7	77793728-77798580	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA062625	Approved				Breast cancer:3.09e-4 (favourable), Glioma:8.70e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 56.4	Expressed in all		
S1PR4	EDG6	ENSG00000125910	Sphingosine-1-phosphate receptor 4	19	3172346-3180332	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA060601, HPA067232			Uncertain	Mitochondria	Head and neck cancer:1.45e-6 (favourable), Cervical cancer:1.33e-4 (favourable), Endometrial cancer:2.22e-4 (favourable), Renal cancer:2.87e-4 (unfavourable), Breast cancer:3.13e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 18.1;spleen: 26.4	appendix: 14.0	Cell line enhanced		HDLM-2: 22.2;HL-60: 25.5;NB-4: 19.9;REH: 81.1;U-937: 23.6
TTC23	FLJ12572, HCC-8	ENSG00000103852	Tetratricopeptide repeat domain 23	15	99136323-99251223	Predicted intracellular proteins	Evidence at protein level	HPA039806, HPA040369	Uncertain		Approved	Plasma membrane<br>Cytosol	Endometrial cancer:1.07e-4 (favourable), Breast cancer:3.17e-4 (favourable)	Expressed in all	Mixed			testis: 24.3	Mixed		
CCDC69	DKFZP434C171, FLJ13705	ENSG00000198624	Coiled-coil domain containing 69	5	151181052-151224145	Predicted intracellular proteins	Evidence at protein level	HPA043648, HPA052896	Uncertain		Approved	Golgi apparatus<br>Plasma membrane<br>Actin filaments	Breast cancer:3.21e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 112.8	Cell line enhanced		ASC diff: 80.3;Daudi: 136.8;U-266/70: 89.8;U-698: 84.7
PML	MYL, RNF71, TRIM19	ENSG00000140464	Promyelocytic leukemia	15	73994673-74047812	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008312, CAB010194, CAB016304	Supported		Enhanced	Nuclear bodies	Renal cancer:6.27e-8 (unfavourable), Breast cancer:3.24e-4 (favourable), Pancreatic cancer:3.29e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 45.1	Expressed in all		
GTF2IRD2B		ENSG00000174428	GTF2I repeat domain containing 2B	7	75092573-75149817	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA056679, HPA056680			Approved	Nucleoplasm	Breast cancer:3.27e-4 (favourable)	Mixed	Expressed in all			ovary: 40.5	Expressed in all		
GSAP	LOC54103, PION	ENSG00000186088	Gamma-secretase activating protein	7	77310751-77416400	Predicted intracellular proteins	Evidence at protein level	HPA023994			Supported	Vesicles	Urothelial cancer:4.15e-5 (favourable), Breast cancer:3.36e-4 (favourable), Renal cancer:3.51e-4 (unfavourable)	Expressed in all	Mixed			lung: 26.8	Cell line enhanced		U-937: 13.1
SLC28A3	CNT3	ENSG00000197506	Solute carrier family 28 member 3	9	84275457-84340683	Predicted membrane proteins, Transporters	Evidence at protein level	HPA023311, HPA024729	Approved				Breast cancer:3.37e-4 (favourable)	Mixed	Tissue enhanced		breast: 10.7;gallbladder: 11.7;skin: 9.8	bone marrow: 6.2	Cell line enriched	8	HMC-1: 51.9
WDR89	C14orf150, MGC9907	ENSG00000140006	WD repeat domain 89	14	63597039-63641861	Predicted intracellular proteins	Evidence at protein level	HPA000813	Uncertain		Approved	Intermediate filaments<br>Cytosol	Liver cancer:3.26e-4 (unfavourable), Breast cancer:3.37e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 20.6	Expressed in all		
DHX58	D11LGP2, LGP2	ENSG00000108771	DExH-box helicase 58	17	42101404-42112733	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018670, HPA019570	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Breast cancer:3.45e-4 (favourable)	Expressed in all	Expressed in all			spleen: 24.9	Cell line enhanced		BJ hTERT+ SV40 Large T+: 42.1;BJ hTERT+ SV40 Large T+ RasG12V: 51.2
DOC2B	DOC2BL	ENSG00000272636	Double C2 domain beta	17	142789-181636	Predicted intracellular proteins	Evidence at protein level	HPA043168	Uncertain				Breast cancer:3.45e-4 (favourable), Head and neck cancer:8.68e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 14.4	Group enriched	8	HAP1: 9.4;SH-SY5Y: 39.6
GIMAP2	DKFZp586D0824, HIMAP2, IAN12, IMAP2	ENSG00000106560	GTPase, IMAP family member 2	7	150685697-150693641	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013589	Approved				Renal cancer:1.29e-4 (unfavourable), Breast cancer:3.50e-4 (favourable)	Expressed in all	Mixed			lymph node: 88.0	Cell line enhanced		HUVEC TERT2: 52.1;MOLT-4: 63.1;REH: 30.9
ZNF394	FLJ12298, ZKSCAN14, ZSCAN46	ENSG00000160908	Zinc finger protein 394	7	99486519-99500324	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051421, HPA054639	Uncertain		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:1.09e-4 (favourable), Lung cancer:2.11e-4 (favourable), Breast cancer:3.56e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 62.0	Expressed in all		
BIRC3	API2, c-IAP2, cIAP2, hiap-1, MALT2, MIHC, RNF49	ENSG00000023445	Baculoviral IAP repeat containing 3	11	102317450-102339403	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002317	Enhanced	Approved	Supported	Nucleoplasm<br>Cytosol	Renal cancer:6.66e-6 (unfavourable), Pancreatic cancer:3.03e-4 (unfavourable), Breast cancer:3.60e-4 (favourable), Colorectal cancer:9.35e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 138.1	appendix: 117.5	Cell line enhanced		CAPAN-2: 106.1;Daudi: 77.5;HDLM-2: 96.2;hTERT-HME1: 79.1
NAT6	FUS2	ENSG00000243477	N-acetyltransferase 6	3	50296402-50299421	Predicted intracellular proteins	Evidence at protein level	HPA039576	Approved				Renal cancer:1.71e-4 (favourable), Breast cancer:3.62e-4 (favourable)	Expressed in all	Expressed in all			testis: 45.8	Expressed in all		
MT-ND1	MTND1, NAD1, ND1	ENSG00000198888	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	MT	3307-4262	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB033779	Approved				Pancreatic cancer:3.26e-4 (favourable), Breast cancer:3.63e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 23817.4	Expressed in all		
TTYH1		ENSG00000167614	Tweety family member 1	19	54415219-54436900	Predicted membrane proteins, Transporters	Evidence at protein level	HPA023617, HPA050655	Approved				Breast cancer:3.64e-4 (favourable)	Tissue enriched	Tissue enriched	27	cerebral cortex: 57.7	fallopian tube,testis: 2.1	Group enriched	6	AF22: 5.8;AN3-CA: 17.4;U-2 OS: 7.0
SELL	CD62L, hLHRc, LAM-1, LAM1, Leu-8, LNHR, LSEL, Lyam-1, LYAM1, PLNHR	ENSG00000188404	Selectin L	1	169690667-169711698	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002144, HPA051972	Enhanced		Approved	Cytosol	Renal cancer:4.96e-5 (unfavourable), Cervical cancer:2.25e-4 (favourable), Ovarian cancer:3.14e-4 (favourable), Breast cancer:3.76e-4 (favourable), Head and neck cancer:6.43e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 254.9;spleen: 219.3;tonsil: 179.1	appendix: 152.7	Cell line enhanced		EFO-21: 9.7;MOLT-4: 16.7;U-266/70: 28.0;U-698: 12.2
TBC1D10C	Carabin, EPI64C, FLJ00332	ENSG00000175463	TBC1 domain family member 10C	11	67403915-67410089	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA069743	Enhanced		Approved	Nuclear bodies	Renal cancer:4.35e-7 (unfavourable), Head and neck cancer:1.86e-5 (favourable), Breast cancer:3.83e-4 (favourable), Cervical cancer:4.20e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 45.6;spleen: 37.9	appendix: 22.0	Cell line enhanced		MOLT-4: 34.1;NB-4: 32.0;U-937: 16.2
CCR7	BLR2, CD197, CDw197, CMKBR7, EBI1	ENSG00000126353	C-C motif chemokine receptor 7	17	40553769-40565472	Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB003796, HPA031383, HPA074467	Enhanced		Supported	Mitochondria	Head and neck cancer:7.61e-7 (favourable), Cervical cancer:8.03e-6 (favourable), Breast cancer:3.84e-4 (favourable), Testis cancer:7.72e-4 (unfavourable)	Mixed	Group enriched	6	appendix: 88.8;lymph node: 97.1;spleen: 39.3;tonsil: 77.2	urinary bladder: 12.4	Cell line enriched	79	HDLM-2: 1284.5
CD48	BCM1, BLAST, hCD48, mCD48, SLAMF2	ENSG00000117091	CD48 molecule	1	160678746-160711851	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002497, HPA055146	Enhanced		Supported	Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol	Renal cancer:3.36e-4 (unfavourable), Breast cancer:3.91e-4 (favourable), Colorectal cancer:4.17e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 311.4;spleen: 213.1;tonsil: 226.0	appendix: 148.5	Cell line enhanced		Daudi: 153.4;HMC-1: 202.6;U-266/70: 372.1;U-266/84: 244.7
C3orf62	FLJ43654	ENSG00000188315	Chromosome 3 open reading frame 62	3	49268602-49277909	Predicted intracellular proteins	Evidence at protein level	HPA043328			Approved	Nuclear speckles	Urothelial cancer:1.62e-5 (favourable), Stomach cancer:3.29e-5 (favourable), Breast cancer:3.93e-4 (favourable), Liver cancer:5.20e-4 (unfavourable), Pancreatic cancer:8.15e-4 (favourable), Lung cancer:8.88e-4 (favourable), Head and neck cancer:9.72e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 28.5	ovary: 8.8	Expressed in all		
STK39	DCHT, SPAK	ENSG00000198648	Serine/threonine kinase 39	2	167954020-168248141	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB046022, HPA061803, HPA062802	Enhanced		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Liver cancer:5.67e-5 (unfavourable), Breast cancer:3.96e-4 (favourable)	Expressed in all	Mixed			testis: 71.4	Mixed		
CST1		ENSG00000170373	Cystatin SN	20	23747553-23751268	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB026769, HPA043706, HPA044763	Enhanced				Breast cancer:4.00e-4 (favourable)	Mixed	Tissue enriched	27	salivary gland: 9590.6	gallbladder: 352.0	Cell line enhanced		CACO-2: 139.8;RT4: 891.2;TIME: 178.3
WLS	C1orf139, EVI, FLJ23091, GPR177, mig-14, MRP, wls	ENSG00000116729	Wntless Wnt ligand secretion mediator	1	68098473-68233120	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA069520	Approved				Renal cancer:3.67e-7 (favourable), Urothelial cancer:3.51e-4 (unfavourable), Breast cancer:4.03e-4 (favourable), Ovarian cancer:9.43e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 163.8	Cell line enhanced		AF22: 388.0
C19orf66	FLJ11286, RyDEN	ENSG00000130813	Chromosome 19 open reading frame 66	19	10086122-10093252	Predicted intracellular proteins	Evidence at protein level	HPA042001	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:8.96e-11 (unfavourable), Urothelial cancer:1.35e-4 (favourable), Breast cancer:4.04e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 20.5	Cell line enhanced		BJ hTERT+ SV40 Large T+: 44.2;BJ hTERT+ SV40 Large T+ RasG12V: 48.5
SPOCK2	KIAA0275, testican-2	ENSG00000107742	SPARC/osteonectin, cwcv and kazal like domains proteoglycan 2	10	72059035-72089032	Predicted secreted proteins	Evidence at protein level	HPA044605	Supported		Uncertain	Nuclear speckles	Head and neck cancer:1.95e-5 (favourable), Breast cancer:4.05e-4 (favourable), Melanoma:4.72e-4 (favourable), Ovarian cancer:7.19e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 161.8;lung: 127.8	lymph node: 75.1	Group enriched	8	Hep G2: 33.9;SCLC-21H: 79.9
TF	PRO1557, PRO2086	ENSG00000091513	Transferrin	3	133745956-133779006	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001527, HPA005692, CAB009538	Enhanced		Uncertain	Mitochondria	Renal cancer:2.35e-13 (unfavourable), Breast cancer:4.05e-4 (favourable)	Tissue enriched	Tissue enriched	14	liver: 5391.9	cerebral cortex: 385.9	Cell line enriched	50	Hep G2: 842.8
CD5	LEU1, T1	ENSG00000110448	CD5 molecule	11	61102395-61127852	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB015392, CAB020308, HPA043416, HPA060839	Enhanced				Head and neck cancer:7.41e-6 (favourable), Renal cancer:8.94e-5 (unfavourable), Endometrial cancer:9.00e-5 (favourable), Cervical cancer:9.16e-5 (favourable), Melanoma:3.93e-4 (favourable), Breast cancer:4.05e-4 (favourable)	Mixed	Tissue enhanced		appendix: 29.8;lymph node: 43.0	tonsil: 20.2	Cell line enriched	71	MOLT-4: 56.4
CYP4F11		ENSG00000171903	Cytochrome P450 family 4 subfamily F member 11	19	15912367-15934867	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA017265, CAB033648, HPA058960	Enhanced				Breast cancer:4.05e-4 (favourable), Pancreatic cancer:9.28e-4 (unfavourable)	Mixed	Tissue enhanced		gallbladder: 29.5;liver: 32.7;small intestine: 26.3	epididymis: 20.0	Cell line enhanced		A-431: 11.4;CAPAN-2: 44.2;EFO-21: 17.4;Hep G2: 17.0;RT4: 12.1
TMEM156	FLJ23235	ENSG00000121895	Transmembrane protein 156	4	38966744-39032922	Predicted membrane proteins	Evidence at transcript level						Breast cancer:4.09e-4 (favourable)	Mixed	Group enriched	5	appendix: 11.8;lymph node: 27.8;spleen: 15.2;tonsil: 24.3;urinary bladder: 5.7	gallbladder: 3.0	Cell line enhanced		Daudi: 28.3;HBEC3-KT: 59.6;hTERT-HME1: 48.9;PC-3: 34.1;U-698: 30.9
TRAF3IP3	T3JAM	ENSG00000009790	TRAF3 interacting protein 3	1	209756032-209782320	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040796	Enhanced		Approved	Vesicles	Breast cancer:4.11e-4 (favourable), Lung cancer:8.15e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 114.8;spleen: 82.5;tonsil: 82.8	appendix: 67.8	Cell line enhanced		HDLM-2: 106.9;Karpas-707: 33.1;MOLT-4: 48.2;NB-4: 43.3;THP-1: 43.1;U-266/70: 51.7
MLLT6	AF17, FLJ23480	ENSG00000275023	MLLT6, PHD finger domain containing	17	38705542-38729803	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA004021	Approved		Approved	Nucleus	Head and neck cancer:3.98e-4 (favourable), Breast cancer:4.18e-4 (favourable), Pancreatic cancer:7.41e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 36.4	Expressed in all		
PIGBOS1		ENSG00000225973	PIGB opposite strand 1	15	55317184-55319161	Predicted intracellular proteins	Evidence at transcript level						Breast cancer:4.19e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 26.2	Expressed in all		
NEK10	FLJ32685	ENSG00000163491	NIMA related kinase 10	3	27110085-27369460	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038941	Uncertain		Approved	Nucleoplasm<br>Vesicles	Breast cancer:4.20e-4 (favourable)	Tissue enriched	Tissue enhanced		testis: 65.9	breast: 18.6	Cell line enhanced		LHCN-M2: 6.8;U-2 OS: 7.1
FCMR	FAIM3, TOSO	ENSG00000162894	Fc fragment of IgM receptor	1	206904386-206923247	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003910	Approved		Approved	Nucleus<br>Focal adhesion sites<br>Cytosol	Breast cancer:4.23e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 175.8;spleen: 148.0;tonsil: 146.7	appendix: 88.1	Group enriched	5	RPMI-8226: 97.7;U-266/70: 51.8
IKZF1	hIk-1, Hs.54452, IKAROS, LyF-1, PPP1R92, ZNFN1A1	ENSG00000185811	IKAROS family zinc finger 1	7	50304124-50405101	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	CAB009247, HPA035221, HPA035222	Enhanced		Supported	Nucleoplasm	Cervical cancer:2.02e-4 (favourable), Breast cancer:4.28e-4 (favourable), Head and neck cancer:8.63e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 83.0	tonsil: 55.9	Cell line enhanced		HDLM-2: 172.0;HMC-1: 152.5;MOLT-4: 116.9;REH: 122.5;U-698: 108.4
HLA-DOB		ENSG00000241106	Major histocompatibility complex, class II, DO beta	6	32812763-32817048	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013846	Enhanced				Renal cancer:3.15e-5 (unfavourable), Ovarian cancer:4.17e-5 (favourable), Breast cancer:4.29e-4 (favourable)	Expressed in all	Group enriched	5	lymph node: 19.6;spleen: 18.6;tonsil: 30.7;urinary bladder: 8.3	colon: 3.5	Cell line enhanced		Daudi: 37.8;U-698: 12.8;U-937: 6.1
MAFF	hMafF	ENSG00000185022	MAF bZIP transcription factor F	22	38200767-38216511	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB025341, HPA055371	Approved		Approved	Nucleus<br>Mitochondria	Breast cancer:4.32e-4 (favourable)	Expressed in all	Mixed			gallbladder: 66.3	Cell line enhanced		hTEC/SVTERT24-B: 79.2;SK-MEL-30: 75.4
PLA2G2D	sPLA2S	ENSG00000117215	Phospholipase A2 group IID	1	20111939-20119566	Enzymes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level						Cervical cancer:8.15e-5 (favourable), Breast cancer:4.35e-4 (favourable), Endometrial cancer:9.74e-4 (favourable)	Tissue enriched	Tissue enhanced		lymph node: 118.5;tonsil: 54.0	appendix: 20.5	Cell line enriched	6	RPMI-8226: 5.9
CD2	SRBC	ENSG00000116824	CD2 molecule	1	116754385-116769228	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002430, HPA003883	Enhanced				Renal cancer:4.82e-6 (unfavourable), Endometrial cancer:1.69e-5 (favourable), Melanoma:3.97e-5 (favourable), Head and neck cancer:7.46e-5 (favourable), Cervical cancer:1.47e-4 (favourable), Breast cancer:4.36e-4 (favourable), Ovarian cancer:7.72e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 131.1	tonsil: 70.8	Group enriched	27	HDLM-2: 201.2;MOLT-4: 129.2
AK2		ENSG00000004455	Adenylate kinase 2	1	33007940-33080996	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018479	Approved				Breast cancer:4.37e-4 (favourable), Pancreatic cancer:6.40e-4 (unfavourable), Endometrial cancer:8.65e-4 (unfavourable), Liver cancer:9.32e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 183.3	Expressed in all		
IL33	C9orf26, DKFZp586H0523, DVS27, IL1F11, NF-HEV	ENSG00000137033	Interleukin 33	9	6215786-6257983	Predicted intracellular proteins	Evidence at protein level	CAB007057, HPA024426	Supported				Breast cancer:4.42e-4 (favourable)	Expressed in all	Mixed			placenta: 87.7	Cell line enriched	10	U-2197: 151.4
KRT17	PCHC1	ENSG00000128422	Keratin 17	17	41619437-41624842	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000029, HPA000452, HPA000453, HPA000539, HPA045062	Enhanced		Enhanced	Intermediate filaments	Breast cancer:4.44e-4 (favourable), Renal cancer:5.74e-4 (unfavourable)	Expressed in all	Tissue enhanced		breast: 222.3;seminal vesicle: 226.0;urinary bladder: 322.8	prostate: 115.6	Group enriched	6	hTCEpi: 14378.7;SiHa: 8960.6
CCDC74B	DKFZp434E2321	ENSG00000152076	Coiled-coil domain containing 74B	2	130139287-130145134	Predicted intracellular proteins	Evidence at transcript level	HPA060727			Uncertain	Vesicles	Renal cancer:1.55e-4 (unfavourable), Breast cancer:4.46e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 23.1;testis: 52.0	cervix, uterine: 13.9	Cell line enhanced		SCLC-21H: 12.3;SH-SY5Y: 15.8
KRT15	CK15, K15, K1CO	ENSG00000171346	Keratin 15	17	41513743-41522529	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023910, HPA024554	Enhanced		Supported	Nucleoplasm<br>Intermediate filaments	Breast cancer:4.50e-4 (favourable)	Tissue enhanced	Group enriched	7	breast: 321.5;esophagus: 784.4;skin: 1010.3	prostate: 94.7	Group enriched	12	HaCaT: 732.6;hTCEpi: 454.1
MVP	LRP, VAULT1	ENSG00000013364	Major vault protein	16	29820394-29848039	Cancer-related genes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA002321, CAB002752, CAB022717, HPA064740	Enhanced		Enhanced	Cytosol	Renal cancer:5.49e-5 (favourable), Breast cancer:4.51e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 165.7	Expressed in all		
SAA2-SAA4		ENSG00000255071	SAA2-SAA4 readthrough	11	18231423-18248635	Predicted membrane proteins	Evidence at transcript level	HPA060139	Uncertain				Renal cancer:2.92e-8 (unfavourable), Breast cancer:4.56e-4 (favourable), Glioma:9.87e-4 (unfavourable)	Tissue enriched	Tissue enhanced		adipose tissue: 27.9;cervix, uterine: 22.6;liver: 15.0	breast: 5.4	Cell line enhanced		A-431: 2.3;EFO-21: 1.4
ZNF552	FLJ21603	ENSG00000178935	Zinc finger protein 552	19	57803841-57814913	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043800, HPA053762, HPA072145	Uncertain		Uncertain	Nucleus	Colorectal cancer:2.66e-4 (favourable), Breast cancer:4.57e-4 (favourable), Head and neck cancer:9.96e-4 (favourable)	Expressed in all	Mixed			breast: 33.9	Expressed in all		
C2orf40	augurin, ECRG4	ENSG00000119147	Chromosome 2 open reading frame 40	2	106063246-106078159	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA008546	Uncertain				Breast cancer:4.58e-4 (favourable)	Tissue enriched	Tissue enhanced		seminal vesicle: 116.4;thyroid gland: 128.1	prostate: 61.6	Not detected		
EVA1B	C1orf78, FAM176B, FLJ10647	ENSG00000142694	Eva-1 homolog B	1	36322031-36324154	Predicted intracellular proteins	Evidence at protein level	HPA041928, HPA043537	Approved		Approved	Cytosol	Renal cancer:4.79e-5 (unfavourable), Breast cancer:4.58e-4 (favourable), Liver cancer:4.82e-4 (unfavourable)	Expressed in all	Mixed			placenta: 14.6	Cell line enhanced		BJ: 28.4
PAQR8	C6orf33, LMPB1, MPRB	ENSG00000170915	Progestin and adipoQ receptor family member 8	6	52361421-52407777	Predicted membrane proteins	Evidence at protein level	HPA064625			Supported	Golgi apparatus<br>Plasma membrane	Breast cancer:4.61e-4 (favourable), Urothelial cancer:6.40e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 64.9	Cell line enhanced		Hep G2: 28.4
TUBA3D	H2-ALPHA	ENSG00000075886	Tubulin alpha 3d	2	131476093-131482934	Predicted intracellular proteins	Evidence at protein level	CAB004972, HPA039247, HPA043684, HPA063394	Uncertain		Supported	Microtubules	Renal cancer:4.75e-9 (unfavourable), Breast cancer:4.65e-4 (favourable)	Mixed	Tissue enriched	31	testis: 250.3	epididymis: 8.1	Not detected		
APOBEC3G	bK150C2.7, CEM15, dJ494G10.1, FLJ12740, MDS019	ENSG00000239713	Apolipoprotein B mRNA editing enzyme catalytic subunit 3G	22	39077005-39087743	Predicted intracellular proteins	Evidence at protein level	HPA001812, HPA073637	Approved		Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:8.66e-13 (unfavourable), Endometrial cancer:6.03e-5 (favourable), Cervical cancer:4.70e-4 (favourable), Breast cancer:4.78e-4 (favourable), Urothelial cancer:6.30e-4 (favourable)	Expressed in all	Mixed			lymph node: 46.0	Cell line enhanced		HDLM-2: 29.7;Karpas-707: 30.4
SOCS3	CIS3, Cish3, SOCS-3, SSI-3	ENSG00000184557	Suppressor of cytokine signaling 3	17	78356778-78360077	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB012220, HPA068569	Approved		Approved	Cytosol	Renal cancer:9.34e-9 (unfavourable), Breast cancer:4.80e-4 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 321.5	gallbladder: 297.9	Cell line enhanced		HDLM-2: 142.9
GTF2B	TFIIB	ENSG00000137947	General transcription factor IIB	1	88852932-88891944	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA061626	Enhanced		Supported	Nucleus<br>Nuclear bodies	Breast cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 47.6	Expressed in all		
GLUL	GLNS	ENSG00000135821	Glutamate-ammonia ligase	1	182381704-182392206	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007316, HPA007571, CAB008636	Approved		Supported	Mitochondria<br>Cytosol	Breast cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 851.0	Cell line enhanced		ASC diff: 791.8;ASC TERT1: 567.1;HSkMC: 512.4
GSTZ1	GSTZ1-1, MAAI, MAI	ENSG00000100577	Glutathione S-transferase zeta 1	14	77320884-77331597	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004701	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:1.12e-7 (favourable), Ovarian cancer:3.73e-4 (favourable), Breast cancer:4.93e-4 (favourable)	Expressed in all	Expressed in all			liver: 134.5	Expressed in all		
SH2D2A	F2771, TSAd	ENSG00000027869	SH2 domain containing 2A	1	156806243-156816862	Predicted intracellular proteins	Evidence at protein level						Renal cancer:5.26e-12 (unfavourable), Urothelial cancer:1.31e-4 (favourable), Breast cancer:4.96e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 15.0	lymph node: 10.5	Cell line enhanced		HDLM-2: 42.7;HMC-1: 29.0;Karpas-707: 57.7
TINF2	TIN2	ENSG00000092330	TERF1 interacting nuclear factor 2	14	24239643-24242674	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA059061, HPA069807			Enhanced	Nuclear bodies	Breast cancer:4.96e-4 (favourable)	Expressed in all	Tissue enriched	24	parathyroid gland: 1349.0	smooth muscle: 56.5	Expressed in all		
DPP9		ENSG00000142002	Dipeptidyl peptidase 9	19	4675224-4724673	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036059	Approved		Supported	Cytosol	Renal cancer:3.38e-8 (unfavourable), Endometrial cancer:6.21e-5 (favourable), Stomach cancer:7.72e-5 (favourable), Breast cancer:4.96e-4 (favourable)	Expressed in all	Expressed in all			appendix: 33.1	Expressed in all		
ATF7IP2	FLJ12668	ENSG00000166669	Activating transcription factor 7 interacting protein 2	16	10326434-10483638	Predicted intracellular proteins	Evidence at protein level	HPA041156, HPA041228	Enhanced				Liver cancer:5.68e-5 (favourable), Urothelial cancer:8.57e-5 (favourable), Breast cancer:4.98e-4 (favourable)	Mixed	Tissue enhanced		testis: 35.7	lymph node: 10.3	Mixed		
TFF1	BCEI, D21S21, HP1.A, HPS2, pNR-2, pS2	ENSG00000160182	Trefoil factor 1	21	42362282-42366594	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB002170, HPA003425	Enhanced				Breast cancer:5.00e-4 (favourable), Endometrial cancer:5.67e-4 (favourable)	Group enriched	Tissue enriched	32	stomach: 6419.9	gallbladder: 203.1	Cell line enriched	49	MCF7: 8447.1
KLHL26		ENSG00000167487	Kelch like family member 26	19	18636965-18671714	Predicted intracellular proteins	Evidence at protein level	HPA023074	Uncertain				Renal cancer:1.25e-6 (favourable), Breast cancer:5.01e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 11.2	Mixed		
C14orf93	FLJ12154	ENSG00000100802	Chromosome 14 open reading frame 93	14	22985908-23010166	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002569	Approved		Approved	Nucleus<br>Plasma membrane	Breast cancer:5.05e-4 (favourable)	Expressed in all	Expressed in all			skin: 21.7	Expressed in all		
GSTT2B	GSTT2P	ENSG00000133433	Glutathione S-transferase theta 2B (gene/pseudogene)	22	23957414-23961186	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000750	Uncertain		Supported	Nucleoplasm<br>Cytosol	Breast cancer:5.06e-4 (favourable)	Expressed in all	Tissue enriched	7	breast: 411.1	adrenal gland: 60.8	Cell line enhanced		AN3-CA: 53.0;HHSteC: 68.3;T-47d: 60.4
SKAP1	SCAP1, SKAP55	ENSG00000141293	Src kinase associated phosphoprotein 1	17	48133440-48430275	Predicted intracellular proteins	Evidence at protein level	HPA002969, CAB025882, CAB055513	Enhanced		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Urothelial cancer:3.14e-4 (favourable), Breast cancer:5.07e-4 (favourable)	Mixed	Mixed			lymph node: 33.6	Cell line enhanced		CAPAN-2: 26.1;HDLM-2: 14.7;HMC-1: 11.3;Karpas-707: 11.5;RPMI-8226: 13.6;RPTEC TERT1: 17.6;U-266/70: 11.0
CLSTN3	CDHR14, CSTN3, KIAA0726	ENSG00000139182	Calsyntenin 3	12	7129698-7158945	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.19e-5 (favourable), Renal cancer:4.49e-5 (unfavourable), Breast cancer:5.08e-4 (favourable), Urothelial cancer:8.07e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 126.6	parathyroid gland: 40.3	Mixed		
PSMB8	beta5i, D6S216E, LMP7, PSMB5i, RING10	ENSG00000204264	Proteasome subunit beta 8	6	32840717-32844703	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046995, HPA050327	Enhanced		Approved	Vesicles<br>Cytokinetic bridge	Breast cancer:5.08e-4 (favourable), Endometrial cancer:7.16e-4 (favourable)	Expressed in all	Mixed			lymph node: 23.0	Mixed		
IL24	C49A, FISP, IL-24, IL10B, mda-7, Mob-5, ST16	ENSG00000162892	Interleukin 24	1	206897443-206904139	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025972	Uncertain				Breast cancer:5.09e-4 (favourable)	Mixed	Tissue enhanced		appendix: 17.3;lymph node: 37.1;spleen: 23.4	urinary bladder: 5.4	Cell line enriched	10	BJ hTERT+: 144.5
CCDC74A	FLJ40345	ENSG00000163040	Coiled-coil domain containing 74A	2	131527675-131533666	Predicted intracellular proteins	Evidence at transcript level	HPA060727			Uncertain	Vesicles	Renal cancer:1.70e-7 (unfavourable), Glioma:1.82e-4 (unfavourable), Testis cancer:4.92e-4 (favourable), Breast cancer:5.11e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 55.2;testis: 79.2	parathyroid gland: 27.2	Cell line enhanced		NTERA-2: 28.4;SCLC-21H: 27.2
IFNLR1	CRF2/12, IFNLR, IL-28R1, IL28RA	ENSG00000185436	Interferon lambda receptor 1	1	24154157-24187959	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017319	Uncertain		Approved	Cytosol	Breast cancer:5.12e-4 (favourable)	Expressed in all	Mixed			small intestine: 10.1	Cell line enhanced		U-266/70: 39.6;U-698: 28.0
SUSD3	MGC26847	ENSG00000157303	Sushi domain containing 3	9	93058688-93085138	Predicted membrane proteins	Evidence at protein level	HPA042310	Uncertain		Approved	Nucleus	Breast cancer:5.13e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 91.6	lymph node: 66.4	Cell line enhanced		Daudi: 107.9;NB-4: 49.1;RPMI-8226: 56.9
TMEM42	MGC29956	ENSG00000169964	Transmembrane protein 42	3	44861869-44865670	Predicted membrane proteins	Evidence at transcript level	HPA052569	Uncertain		Uncertain	Nucleoplasm<br>Nucleoli	Renal cancer:1.10e-5 (favourable), Breast cancer:5.23e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 12.8	Mixed		
MATK	CHK, CTK, DKFZp434N1212, HHYLTK, HYL, HYLTK, Lsk, MGC1708, MGC2101	ENSG00000007264	Megakaryocyte-associated tyrosine kinase	19	3777970-3802129	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004847	Approved				Breast cancer:5.27e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 22.0	spleen: 19.8	Cell line enhanced		HL-60: 85.8;K-562: 43.3;NB-4: 47.4;SCLC-21H: 36.7
CUL9	H7AP1, KIAA0708, PARC	ENSG00000112659	Cullin 9	6	43182175-43224587	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016434, HPA052004	Approved		Approved	Cytosol	Head and neck cancer:2.37e-5 (favourable), Colorectal cancer:2.48e-4 (unfavourable), Urothelial cancer:4.87e-4 (favourable), Breast cancer:5.28e-4 (favourable), Pancreatic cancer:8.07e-4 (favourable)	Expressed in all	Mixed			testis: 10.0	Mixed		
TMEM229B	C14orf83, FLJ33387	ENSG00000198133	Transmembrane protein 229B	14	67447084-67533739	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA046562	Approved				Endometrial cancer:1.21e-5 (favourable), Urothelial cancer:1.79e-5 (favourable), Breast cancer:5.38e-4 (favourable)	Expressed in all	Mixed			cervix, uterine: 16.0	Cell line enhanced		U-937: 26.9
PARD6A	PAR-6, PAR-6A, PAR6alpha, TAX40, TIP-40	ENSG00000102981	Par-6 family cell polarity regulator alpha	16	67660946-67662778	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009733, HPA041551	Approved		Supported	Cell Junctions<br>Actin filaments<br>Cytosol	Renal cancer:3.08e-7 (favourable), Breast cancer:5.40e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 20.2	cerebral cortex: 12.1	Cell line enhanced		REH: 24.9;SCLC-21H: 25.2
ING2	ING1L, p33ING2	ENSG00000168556	Inhibitor of growth family member 2	4	183504994-183511096	Predicted intracellular proteins	Evidence at protein level	HPA019486, HPA021517	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Breast cancer:5.43e-4 (favourable), Liver cancer:8.87e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 63.3	Expressed in all		
TPRG1	FAM79B, FLJ41238, FLJ43694	ENSG00000188001	Tumor protein p63 regulated 1	3	188947214-189325304	Predicted intracellular proteins	Evidence at protein level	HPA044751, HPA060187	Uncertain		Supported	Nucleoplasm	Breast cancer:5.43e-4 (favourable)	Tissue enhanced	Tissue enhanced		esophagus: 49.1	breast: 28.4	Cell line enhanced		HDLM-2: 8.9;Karpas-707: 3.3;T-47d: 3.9;U-266/70: 3.5
RCL1	RNAC, RPCL1	ENSG00000120158	RNA terminal phosphate cyclase like 1	9	4792869-4885917	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA071308			Approved	Nucleoplasm	Renal cancer:2.40e-7 (favourable), Breast cancer:5.48e-4 (favourable), Liver cancer:8.02e-4 (favourable)	Expressed in all	Expressed in all			liver: 123.7	Expressed in all		
APOD		ENSG00000189058	Apolipoprotein D	3	195568702-195584205	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA040520	Enhanced		Approved	Plasma membrane	Thyroid cancer:4.12e-4 (unfavourable), Breast cancer:5.51e-4 (favourable), Stomach cancer:6.02e-4 (unfavourable)	Expressed in all	Tissue enriched	7	breast: 4620.2	adipose tissue: 670.2	Cell line enhanced		ASC diff: 1866.1;ASC TERT1: 1018.4;WM-115: 301.1
YBEY	C21orf57	ENSG00000182362	YbeY metallopeptidase (putative)	21	46286337-46297751	Predicted intracellular proteins	Evidence at protein level	HPA016593, HPA018162	Uncertain		Enhanced	Nucleoplasm	Breast cancer:5.54e-4 (favourable)	Expressed in all	Expressed in all			testis: 92.0	Mixed		
HLA-DQB2	HLA-DXB	ENSG00000232629	Major histocompatibility complex, class II, DQ beta 2	6	32756098-32763534	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Breast cancer:5.55e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 8.1;skin: 13.3	tonsil: 5.9	Not detected		
PLGRKT	AD025, C9orf46, FLJ14688, MDS030, Plg-RKT	ENSG00000107020	Plasminogen receptor with a C-terminal lysine	9	5357973-5437878	Predicted intracellular proteins	Evidence at protein level	HPA008214, HPA011144	Enhanced		Uncertain	Mitochondria	Renal cancer:5.09e-5 (favourable), Breast cancer:5.56e-4 (favourable)	Expressed in all	Expressed in all			rectum: 55.2	Cell line enhanced		HDLM-2: 245.6
FHL3	SLIM2	ENSG00000183386	Four and a half LIM domains 3	1	37996770-38005606	Predicted intracellular proteins	Evidence at protein level	HPA045723			Approved	Nucleus	Renal cancer:4.20e-11 (unfavourable), Liver cancer:8.59e-5 (unfavourable), Breast cancer:5.62e-4 (favourable)	Expressed in all	Tissue enriched	13	skeletal muscle: 569.1	smooth muscle: 43.5	Mixed		
GPR27	SREB1	ENSG00000170837	G protein-coupled receptor 27	3	71754050-71756496	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA029395	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Actin filaments<br>Cytosol	Ovarian cancer:1.21e-6 (favourable), Breast cancer:5.63e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 46.5	cerebral cortex: 24.9	Cell line enhanced		EFO-21: 17.2;HL-60: 14.7;NTERA-2: 30.5;SH-SY5Y: 12.3
CLTA	Lca	ENSG00000122705	Clathrin light chain A	9	36190856-36304781	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002665, HPA050918, HPA054667	Enhanced		Enhanced	Vesicles<br>Endosomes<br>Lysosomes	Liver cancer:9.46e-5 (unfavourable), Thyroid cancer:1.01e-4 (favourable), Breast cancer:5.64e-4 (favourable)	Expressed in all	Expressed in all			placenta: 178.0	Expressed in all		
TNIP1	ABIN-1, KIAA0113, NAF1, VAN	ENSG00000145901	TNFAIP3 interacting protein 1	5	151029945-151093577	Predicted intracellular proteins	Evidence at protein level	HPA037893, HPA037894, HPA071950	Approved		Supported	Nucleoplasm<br>Cytosol	Endometrial cancer:6.86e-5 (favourable), Breast cancer:5.69e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 132.2	Expressed in all		
CDK14	PFTAIRE1, PFTK1	ENSG00000058091	Cyclin dependent kinase 14	7	90466424-91210590	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015267	Approved		Supported	Nucleus<br>Cytosol	Breast cancer:5.86e-4 (favourable), Stomach cancer:7.79e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 56.7	Mixed		
STAT5A	MGF, STAT5	ENSG00000126561	Signal transducer and activator of transcription 5A	17	42287547-42311943	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB003860, HPA027873, HPA042128, HPA049883, HPA051156	Approved		Enhanced	Nucleoplasm<br>Cytosol	Breast cancer:5.87e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 90.3	Cell line enhanced		HDLM-2: 100.4;HEL: 145.8;K-562: 246.3;MOLT-4: 160.1
ZNF688		ENSG00000229809	Zinc finger protein 688	16	30569346-30572734	Predicted intracellular proteins	Evidence at transcript level	HPA048922	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cell Junctions	Endometrial cancer:4.58e-5 (favourable), Lung cancer:3.24e-4 (favourable), Breast cancer:5.90e-4 (favourable), Pancreatic cancer:6.61e-4 (favourable), Cervical cancer:7.74e-4 (favourable)	Expressed in all	Expressed in all			testis: 23.7	Expressed in all		
CASP9	APAF-3, ICE-LAP6, MCH6, PPP1R56	ENSG00000132906	Caspase 9	1	15490832-15526534	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001473, CAB004348, HPA046488	Approved		Approved	Mitochondria	Urothelial cancer:1.67e-5 (favourable), Breast cancer:5.91e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 37.1	Expressed in all		
S1PR3	EDG-3, EDG3	ENSG00000213694	Sphingosine-1-phosphate receptor 3	9	88991447-89005010	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level						Renal cancer:7.91e-6 (unfavourable), Colorectal cancer:1.30e-4 (unfavourable), Breast cancer:5.91e-4 (favourable)	Expressed in all	Mixed			smooth muscle: 52.4	Cell line enhanced		AF22: 117.8;ASC diff: 111.7;ASC TERT1: 114.8
ARHGEF1	LBCL2, P115-RHOGEF, SUB1.5	ENSG00000076928	Rho guanine nucleotide exchange factor 1	19	41883161-41930150	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009502, HPA012924, HPA060784	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Renal cancer:3.36e-8 (unfavourable), Breast cancer:5.92e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 144.9	Expressed in all		
MITD1	LOC129531	ENSG00000158411	Microtubule interacting and trafficking domain containing 1	2	99161427-99181058	Predicted intracellular proteins	Evidence at protein level	HPA036162, HPA036163	Approved		Enhanced	Vesicles	Renal cancer:1.32e-11 (unfavourable), Urothelial cancer:5.46e-8 (favourable), Liver cancer:1.47e-6 (unfavourable), Breast cancer:5.96e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 42.2	Expressed in all		
NR4A3	CHN, CSMF, MINOR, NOR1	ENSG00000119508	Nuclear receptor subfamily 4 group A member 3	9	99821855-99866891	Cancer-related genes, Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043360	Uncertain				Breast cancer:5.97e-4 (favourable)	Mixed	Tissue enhanced		adrenal gland: 88.9	urinary bladder: 42.2	Cell line enhanced		BJ hTERT+: 21.0;SK-MEL-30: 14.0;U-266/70: 7.9
WNT11		ENSG00000085741	Wnt family member 11	11	76186325-76210736	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA050101, HPA063569	Uncertain		Approved	Centrosome<br>Cytosol	Breast cancer:5.97e-4 (favourable)	Mixed	Tissue enhanced		adipose tissue: 29.7;adrenal gland: 17.3	placenta: 5.7	Cell line enhanced		BEWO: 34.3;CAPAN-2: 15.3;EFO-21: 53.0
NFKBID	IkappaBNS, TA-NFKBH	ENSG00000167604	NFKB inhibitor delta	19	35887653-35902303	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043573			Approved	Mitochondria	Urothelial cancer:8.34e-6 (favourable), Head and neck cancer:5.43e-4 (favourable), Breast cancer:6.01e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 9.8	appendix: 5.9	Mixed		
LRRC23	B7, LRPB7	ENSG00000010626	Leucine rich repeat containing 23	12	6873569-6914243	Predicted intracellular proteins	Evidence at protein level	HPA037766, HPA057533	Enhanced		Supported	Nucleoli	Breast cancer:6.02e-4 (favourable)	Expressed in all	Group enriched	7	fallopian tube: 165.3;testis: 43.3	epididymis: 15.2	Mixed		
PNRC2		ENSG00000189266	Proline rich nuclear receptor coactivator 2	1	23959109-23963462	Predicted intracellular proteins	Evidence at protein level	HPA027820, HPA045837	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus	Liver cancer:7.97e-5 (unfavourable), Melanoma:1.41e-4 (unfavourable), Urothelial cancer:4.05e-4 (favourable), Breast cancer:6.02e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 203.4	Expressed in all		
DAXX	DAP6	ENSG00000204209	Death domain associated protein	6	33318558-33329286	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB002224, HPA008736, HPA008797, CAB025546, HPA065779	Enhanced		Enhanced	Nucleus<br>Nuclear bodies	Renal cancer:6.32e-7 (unfavourable), Breast cancer:6.05e-4 (favourable)	Expressed in all	Mixed			epididymis: 19.3	Mixed		
IGLL5		ENSG00000254709	Immunoglobulin lambda like polypeptide 5	22	22887780-22896107	Predicted intracellular proteins	Evidence at protein level						Renal cancer:5.94e-8 (unfavourable), Head and neck cancer:3.41e-5 (favourable), Breast cancer:6.10e-4 (favourable)	Expressed in all	Tissue enhanced		tonsil: 836.2	urinary bladder: 638.6	Group enriched	7	Daudi: 472.9;U-266/70: 346.8;U-698: 308.3
CBX7		ENSG00000100307	Chromobox 7	22	39120167-39152674	Predicted intracellular proteins	Evidence at protein level	CAB011574, HPA048677, HPA056480	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.45e-5 (favourable), Pancreatic cancer:1.04e-4 (favourable), Cervical cancer:3.63e-4 (favourable), Colorectal cancer:3.73e-4 (unfavourable), Breast cancer:6.18e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 81.6	Cell line enhanced		HDLM-2: 34.6
TXLNA	DKFZp451J0118	ENSG00000084652	Taxilin alpha	1	32179686-32198285	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA045383, HPA072477	Enhanced		Approved	Nucleoplasm<br>Centrosome<br>Cytosol	Renal cancer:7.21e-7 (unfavourable), Liver cancer:1.57e-6 (unfavourable), Pancreatic cancer:8.69e-5 (favourable), Head and neck cancer:5.53e-4 (favourable), Breast cancer:6.24e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 48.1	Expressed in all		
CLDN11	OSP, OTM	ENSG00000013297	Claudin 11	3	170418865-170860380	Predicted membrane proteins	Evidence at protein level	CAB009789, HPA013166	Enhanced				Breast cancer:6.31e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 89.0;testis: 183.6	ovary: 61.7	Cell line enhanced		ASC diff: 254.1;ASC TERT1: 324.5;EFO-21: 266.5;HUVEC TERT2: 345.5;TIME: 539.4
GDPGP1	C15orf58	ENSG00000183208	GDP-D-glucose phosphorylase 1	15	90233808-90245811	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048189, HPA059841	Approved		Approved	Cytosol	Breast cancer:6.32e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 9.6	Mixed		
SVBP	CCDC23, MGC45441	ENSG00000177868	Small vasohibin binding protein	1	42807052-42817252	Predicted intracellular proteins	Evidence at protein level	HPA008507	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Liver cancer:1.18e-4 (unfavourable), Breast cancer:6.33e-4 (favourable)	Expressed in all	Expressed in all			testis: 79.8	Expressed in all		
CD3G		ENSG00000160654	CD3g molecule	11	118344344-118355161	CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017520, HPA038494	Enhanced				Renal cancer:9.33e-5 (unfavourable), Cervical cancer:2.61e-4 (favourable), Head and neck cancer:3.00e-4 (favourable), Breast cancer:6.33e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 31.4;tonsil: 18.8	spleen: 16.1	Cell line enriched	69	MOLT-4: 160.9
CXCL9	CMK, crg-10, Humig, MIG, SCYB9	ENSG00000138755	C-X-C motif chemokine ligand 9	4	76001275-76007488	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:5.15e-6 (unfavourable), Endometrial cancer:2.07e-4 (favourable), Breast cancer:6.36e-4 (favourable), Ovarian cancer:8.06e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 327.4	appendix: 86.2	Not detected		
DHRS7	retDSR4, SDR34C1	ENSG00000100612	Dehydrogenase/reductase 7	14	60144120-60169856	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA031121	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:1.92e-10 (favourable), Head and neck cancer:2.51e-4 (unfavourable), Breast cancer:6.42e-4 (favourable), Ovarian cancer:7.99e-4 (unfavourable)	Tissue enriched	Expressed in all			prostate: 650.0	Expressed in all		
BEX1		ENSG00000133169	Brain expressed X-linked 1	X	103062651-103064240	Predicted intracellular proteins	Evidence at protein level	HPA045384	Approved				Renal cancer:8.16e-8 (favourable), Breast cancer:6.43e-4 (favourable), Thyroid cancer:6.88e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 505.2	parathyroid gland: 154.3	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 525.2;HBF TERT88: 582.7;HL-60: 1113.6;SCLC-21H: 490.1
IRF4	LSIRF, MUM1	ENSG00000137265	Interferon regulatory factor 4	6	391739-411447	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002038, HPA002698, CAB013508	Enhanced		Supported	Nucleoplasm	Head and neck cancer:1.64e-6 (favourable), Breast cancer:6.44e-4 (favourable)	Tissue enriched	Tissue enhanced		lymph node: 27.1	tonsil: 24.1	Group enriched	5	HDLM-2: 204.2;Karpas-707: 141.1;RPMI-8226: 136.6;U-266/70: 134.4;U-266/84: 98.3;U-698: 40.9;WM-115: 106.9
BMP6	VGR, VGR1	ENSG00000153162	Bone morphogenetic protein 6	6	7726797-7881422	Predicted secreted proteins	Evidence at protein level	CAB002773, HPA062683	Approved		Approved	Mitochondria	Breast cancer:6.45e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 33.4	lung: 10.4	Cell line enhanced		HUVEC TERT2: 162.0;Karpas-707: 72.0;SiHa: 90.3;TIME: 73.2
ADGRB2	BAI2	ENSG00000121753	Adhesion G protein-coupled receptor B2	1	31727117-31764893	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA052612, HPA054617			Supported	Centrosome	Lung cancer:4.02e-5 (unfavourable), Breast cancer:6.46e-4 (favourable)	Tissue enhanced	Tissue enriched	14	cerebral cortex: 72.3	adrenal gland: 5.1	Cell line enhanced		SH-SY5Y: 26.4;T-47d: 27.3;U-2 OS: 28.9
C19orf47	FLJ36888	ENSG00000160392	Chromosome 19 open reading frame 47	19	40319536-40348527	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041843, HPA046309	Uncertain		Enhanced	Nucleoplasm	Endometrial cancer:7.10e-5 (unfavourable), Liver cancer:1.41e-4 (unfavourable), Breast cancer:6.50e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 63.7	Expressed in all		
NXNL2	C9orf121	ENSG00000130045	Nucleoredoxin-like 2	9	88535101-88584274	Predicted intracellular proteins	Evidence at transcript level	HPA045526	Uncertain		Approved	Cytosol	Endometrial cancer:3.83e-8 (favourable), Breast cancer:6.53e-4 (favourable), Renal cancer:9.60e-4 (favourable)	Group enriched	Mixed			adipose tissue: 7.7	Cell line enhanced		RPTEC TERT1: 7.9
TLN2	ILWEQ, KIAA0320	ENSG00000171914	Talin 2	15	62390526-62844631	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017194, HPA051828, HPA054787	Enhanced		Supported	Focal adhesion sites<br>Cytosol	Renal cancer:1.81e-6 (favourable), Breast cancer:6.53e-4 (favourable), Stomach cancer:7.74e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 41.2;kidney: 41.1	thyroid gland: 21.7	Mixed		
TRIM47	GOA, RNF100	ENSG00000132481	Tripartite motif containing 47	17	75874161-75878575	Predicted intracellular proteins	Evidence at protein level	HPA014933	Uncertain		Supported	Cytosol	Liver cancer:5.59e-5 (unfavourable), Renal cancer:9.69e-5 (unfavourable), Breast cancer:6.54e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 23.8	Mixed		
CST7		ENSG00000077984	Cystatin F	20	24949230-24959928	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA040442	Enhanced				Renal cancer:4.37e-6 (unfavourable), Endometrial cancer:9.17e-6 (favourable), Head and neck cancer:5.85e-5 (favourable), Breast cancer:6.55e-4 (favourable), Cervical cancer:7.90e-4 (favourable)	Expressed in all	Tissue enriched	9	bone marrow: 642.9	spleen: 74.1	Group enriched	19	HL-60: 58.5;HMC-1: 170.9;NB-4: 126.6;U-937: 278.1
BST2	CD317, tetherin	ENSG00000130303	Bone marrow stromal cell antigen 2	19	17402939-17405648	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA017060	Approved		Supported	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:3.56e-9 (unfavourable), Testis cancer:4.22e-4 (unfavourable), Breast cancer:6.69e-4 (favourable)	Expressed in all	Expressed in all			ovary: 586.7	Mixed		
SLC39A8	BIGM103	ENSG00000138821	Solute carrier family 39 member 8	4	102251041-102431258	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038832, HPA038833	Approved				Renal cancer:6.34e-6 (favourable), Colorectal cancer:1.34e-4 (favourable), Breast cancer:6.69e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 257.0	cervix, uterine: 129.4	Cell line enhanced		BJ hTERT+: 128.9;Karpas-707: 123.0
UBE2L6	UBCH8	ENSG00000156587	Ubiquitin conjugating enzyme E2 L6	11	57551656-57568284	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003328, CAB073407	Enhanced		Approved	Cytosol	Pancreatic cancer:4.88e-4 (unfavourable), Breast cancer:6.75e-4 (favourable)	Expressed in all	Expressed in all			spleen: 148.0	Mixed		
APOL3	APOLIII, CG12-1	ENSG00000128284	Apolipoprotein L3	22	36140330-36166177	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036228			Approved	Nuclear bodies<br>Mitochondria	Renal cancer:1.23e-5 (unfavourable), Breast cancer:6.82e-4 (favourable)	Expressed in all	Mixed			spleen: 64.0	Cell line enhanced		ASC TERT1: 38.5;Karpas-707: 42.5
CR2	C3DR, CD21	ENSG00000117322	Complement C3d receptor 2	1	207454230-207489895	CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002659, HPA052942, HPA060715	Enhanced				Breast cancer:6.90e-4 (favourable)	Mixed	Group enriched	21	appendix: 68.3;lymph node: 206.0;spleen: 100.2;tonsil: 153.8	kidney: 6.2	Cell line enhanced		Daudi: 17.1;MOLT-4: 10.7;RPMI-8226: 3.2
STARD10	CGI-52, NY-CO-28, PCTP2, SDCCAG28	ENSG00000214530	StAR related lipid transfer domain containing 10	11	72754729-72794168	Predicted intracellular proteins	Evidence at protein level	HPA026661	Uncertain				Breast cancer:6.92e-4 (favourable)	Expressed in all	Expressed in all			rectum: 205.1	Expressed in all		
RP11-211G3.2		ENSG00000223401		3	187743686-187746028	Predicted intracellular proteins	Evidence at transcript level						Breast cancer:6.93e-4 (favourable)	Mixed	Tissue enhanced		skeletal muscle: 8.0	bone marrow: 4.5	Cell line enhanced		Daudi: 2.1;U-698: 4.6
PI3	cementoin, ELAFIN, ESI, SKALP, WAP3, WFDC14	ENSG00000124102	Peptidase inhibitor 3	20	45174876-45176544	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB009449, HPA017737	Enhanced		Approved	Plasma membrane	Renal cancer:1.94e-8 (unfavourable), Ovarian cancer:3.84e-6 (unfavourable), Pancreatic cancer:6.89e-4 (unfavourable), Breast cancer:6.94e-4 (favourable)	Tissue enhanced	Group enriched	15	esophagus: 2285.4;tonsil: 1739.8	appendix: 133.6	Group enriched	7	EFO-21: 78.9;HaCaT: 92.0;PC-3: 163.0
GSTO1	GSTTLp28, P28	ENSG00000148834	Glutathione S-transferase omega 1	10	104235356-104267459	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037603, HPA037604	Enhanced				Renal cancer:2.11e-4 (unfavourable), Breast cancer:6.95e-4 (favourable), Head and neck cancer:8.83e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 266.3	Expressed in all		
ICAM1	BB2, CD54	ENSG00000090339	Intercellular adhesion molecule 1	19	10270835-10286615	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002126, CAB002142, HPA004877	Enhanced		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:1.32e-6 (unfavourable), Breast cancer:7.09e-4 (favourable)	Expressed in all	Expressed in all			lung: 255.9	Cell line enhanced		Karpas-707: 302.5
ZNF516	HsT287, KIAA0222	ENSG00000101493	Zinc finger protein 516	18	76358190-76495190	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015792	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.21e-4 (favourable), Liver cancer:2.79e-4 (unfavourable), Breast cancer:7.09e-4 (favourable), Pancreatic cancer:7.96e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 54.4	Mixed		
ZNF655	VIK, VIK-1	ENSG00000197343	Zinc finger protein 655	7	99558406-99576453	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029534, HPA050750	Uncertain		Supported	Nucleoplasm<br>Plasma membrane	Breast cancer:7.12e-4 (favourable), Melanoma:7.24e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 21.2	Mixed		
SBSPON	C8orf84, RPESP	ENSG00000164764	Somatomedin B and thrombospondin type 1 domain containing	8	73064540-73124088	Predicted secreted proteins	Evidence at protein level	HPA029595, CAB034214, CAB034332	Uncertain		Approved	Vesicles	Breast cancer:7.18e-4 (favourable), Renal cancer:8.82e-4 (unfavourable)	Mixed	Tissue enhanced		prostate: 23.8	urinary bladder: 16.2	Group enriched	6	BJ: 7.6;RPTEC TERT1: 12.1
ITGA10		ENSG00000143127	Integrin subunit alpha 10	1	145891208-145910189	Plasma proteins, Predicted membrane proteins	Evidence at transcript level						Breast cancer:7.18e-4 (favourable)	Tissue enhanced	Mixed			cervix, uterine: 8.1	Cell line enhanced		ASC TERT1: 35.3;HSkMC: 33.5;hTERT-HME1: 31.5;LHCN-M2: 60.2;TIME: 100.9
IFRD2	IFNRP, SKMc15, SM15	ENSG00000214706	Interferon related developmental regulator 2	3	50287732-50292918	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA068560	Approved		Approved	Nucleoplasm	Renal cancer:2.50e-4 (favourable), Breast cancer:7.22e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 28.9	Expressed in all		
GZMB	CCPI, CGL-1, CGL1, CSP-B, CSPB, CTLA1, CTSGL1, HLP, SECT	ENSG00000100453	Granzyme B	14	24630954-24634267	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000376, HPA003418	Enhanced				Renal cancer:1.10e-7 (unfavourable), Endometrial cancer:1.58e-5 (favourable), Breast cancer:7.27e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 40.1	bone marrow,spleen: 36.2	Cell line enriched	6	HMC-1: 17.4
GZMA	CTLA3, HFSP	ENSG00000145649	Granzyme A	5	55102648-55110252	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA054134	Uncertain				Renal cancer:1.26e-6 (unfavourable), Endometrial cancer:6.44e-6 (favourable), Breast cancer:7.27e-4 (favourable)	Expressed in all	Mixed			spleen: 70.9	Cell line enhanced		HL-60: 3.2
DDB2	DDBB, FLJ34321, UV-DDB2, XPE	ENSG00000134574	Damage specific DNA binding protein 2	11	47214465-47239240	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB025912, HPA058406	Enhanced		Supported	Nucleoplasm<br>Cell Junctions	Endometrial cancer:1.20e-4 (favourable), Cervical cancer:1.58e-4 (favourable), Breast cancer:7.29e-4 (favourable)	Expressed in all	Expressed in all			skin: 53.7	Expressed in all		
RGL3	FLJ32585	ENSG00000205517	Ral guanine nucleotide dissociation stimulator like 3	19	11384341-11419342	Predicted intracellular proteins	Evidence at protein level	HPA042763, HPA043615, HPA064578	Uncertain		Uncertain	Nucleus<br>Cytosol	Renal cancer:6.61e-4 (favourable), Breast cancer:7.35e-4 (favourable)	Mixed	Group enriched	6	parathyroid gland: 128.2;thyroid gland: 36.8	seminal vesicle: 13.3	Cell line enhanced		BEWO: 17.4;RT4: 17.3;T-47d: 14.8
KDM4B	JMJD2B, KIAA0876, TDRD14B	ENSG00000127663	Lysine demethylase 4B	19	4969113-5153595	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062872			Supported	Nucleus<br>Cytosol	Endometrial cancer:4.25e-7 (favourable), Melanoma:2.13e-4 (unfavourable), Colorectal cancer:2.74e-4 (unfavourable), Breast cancer:7.39e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 19.9	Expressed in all		
NAB2	MADER	ENSG00000166886	NGFI-A binding protein 2	12	57088894-57095476	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004510, HPA027464	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:9.38e-6 (unfavourable), Breast cancer:7.41e-4 (favourable)	Expressed in all	Expressed in all			ovary: 39.3	Expressed in all		
FAM3D	EF7, OIT1	ENSG00000198643	Family with sequence similarity 3 member D	3	58633946-58666848	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013844	Approved				Head and neck cancer:1.89e-4 (favourable), Breast cancer:7.51e-4 (favourable)	Tissue enhanced	Tissue enhanced		colon: 318.5;rectum: 484.7	salivary gland: 191.6	Not detected		
GBP2		ENSG00000162645	Guanylate binding protein 2	1	89106132-89150456	Predicted intracellular proteins	Evidence at protein level	HPA042682, CAB045975	Supported		Supported	Nucleoplasm<br>Actin filaments<br>Cytosol	Renal cancer:2.14e-10 (unfavourable), Urothelial cancer:1.10e-5 (favourable), Pancreatic cancer:5.73e-5 (unfavourable), Breast cancer:7.57e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 195.5	Cell line enhanced		EFO-21: 57.2;HDLM-2: 65.6;RT4: 69.0
PLAT		ENSG00000104368	Plasminogen activator, tissue type	8	42175233-42207724	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA003412, CAB009335	Supported		Approved	Actin filaments	Renal cancer:4.95e-4 (unfavourable), Breast cancer:7.57e-4 (favourable)	Expressed in all	Tissue enriched	5	parathyroid gland: 709.4	urinary bladder: 135.9	Cell line enhanced		CAPAN-2: 590.7;HMC-1: 372.4;U-2197: 417.3;WM-115: 889.6
CCDC115	ccp1, FLJ30131, MGC12981	ENSG00000136710	Coiled-coil domain containing 115	2	130338241-130342349	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034598	Approved		Supported	Vesicles<br>Plasma membrane	Breast cancer:7.59e-4 (favourable)	Expressed in all	Expressed in all			ovary: 55.5	Expressed in all		
RBMXL1	KAT3	ENSG00000213516	RNA binding motif protein, X-linked like 1	1	88979456-88992960	Predicted intracellular proteins	Evidence at protein level	HPA057707	Supported		Approved	Nucleoplasm	Pancreatic cancer:7.26e-4 (unfavourable), Breast cancer:7.60e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 22.5	Expressed in all		
PLIN5	LSDA5, LSDP5, MLDP, OXPAT	ENSG00000214456	Perilipin 5	19	4522531-4535224	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.97e-4 (favourable), Urothelial cancer:2.16e-4 (favourable), Liver cancer:2.81e-4 (favourable), Breast cancer:7.68e-4 (favourable), Endometrial cancer:8.56e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 34.5;ovary: 42.4	salivary gland: 25.8	Cell line enhanced		BEWO: 3.2;SH-SY5Y: 3.0;T-47d: 5.9
CHAD	SLRR4A	ENSG00000136457	Chondroadherin	17	50464496-50468966	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA018241	Enhanced				Liver cancer:1.59e-4 (favourable), Breast cancer:7.68e-4 (favourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 31.8	adrenal gland: 13.4	Cell line enhanced		RT4: 3.4;SCLC-21H: 10.1
CXCL1	FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3, SCYB1	ENSG00000163739	C-X-C motif chemokine ligand 1	4	73869393-73871242	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.60e-4 (unfavourable), Liver cancer:2.91e-4 (unfavourable), Cervical cancer:7.23e-4 (unfavourable), Breast cancer:7.83e-4 (favourable)	Expressed in all	Tissue enhanced		cervix, uterine: 178.6;spleen: 112.8	urinary bladder: 92.0	Group enriched	7	BJ hTERT+: 658.8;EFO-21: 1914.4;RPTEC TERT1: 559.0
ZNF548	FLJ32932	ENSG00000188785	Zinc finger protein 548	19	57389850-57402992	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA066042	Uncertain		Approved	Nucleus	Breast cancer:7.85e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 32.6	Mixed		
C1RL	C1r-LP, C1RL1	ENSG00000139178	Complement C1r subcomponent like	12	7089587-7109273	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA011338, CAB026172	Supported		Approved	Microtubules<br>Cytosol	Renal cancer:1.52e-7 (unfavourable), Breast cancer:7.92e-4 (favourable)	Expressed in all	Expressed in all			liver: 83.7	Cell line enhanced		HSkMC: 60.9
PCP2	GPSM4, MGC41903	ENSG00000174788	Purkinje cell protein 2	19	7631611-7633748	Predicted intracellular proteins	Evidence at protein level	HPA057428			Approved	Nuclear speckles<br>Vesicles	Urothelial cancer:2.76e-5 (favourable), Breast cancer:7.93e-4 (favourable)	Mixed	Tissue enriched	9	testis: 72.6	skin: 8.1	Cell line enhanced		HMC-1: 7.2;NB-4: 11.1
WIPF3	CR16, FLJ36931	ENSG00000122574	WAS/WASL interacting protein family member 3	7	29806486-29917066	Predicted intracellular proteins	Evidence at protein level	HPA041145, HPA041211	Uncertain		Uncertain	Mitochondria	Breast cancer:7.93e-4 (favourable)	Mixed	Tissue enhanced		ovary: 52.8;testis: 37.3	epididymis: 25.0	Cell line enhanced		HAP1: 19.3;K-562: 6.0;NTERA-2: 5.3;RPMI-8226: 8.0
ZRSR2	U2AF1-RS2, U2AF1L2, URP, ZC3H22	ENSG00000169249	Zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2	X	15790472-15823260	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.87e-5 (unfavourable), Endometrial cancer:8.50e-5 (favourable), Urothelial cancer:2.97e-4 (favourable), Breast cancer:7.96e-4 (favourable)	Expressed in all	Expressed in all			spleen: 34.1	Expressed in all		
RILP	FLJ31193	ENSG00000167705	Rab interacting lysosomal protein	17	1646145-1650077	Predicted intracellular proteins	Evidence at protein level						Renal cancer:8.51e-5 (favourable), Urothelial cancer:7.12e-4 (favourable), Breast cancer:7.97e-4 (favourable)	Expressed in all	Mixed			skeletal muscle: 8.7	Cell line enhanced		HEL: 16.7;HMC-1: 8.2
TIMM9	TIM9A	ENSG00000100575	Translocase of inner mitochondrial membrane 9	14	58408494-58427614	Predicted intracellular proteins	Evidence at protein level	HPA002932	Approved		Enhanced	Mitochondria	Ovarian cancer:6.39e-5 (favourable), Liver cancer:9.89e-5 (unfavourable), Breast cancer:8.04e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 53.7	Expressed in all		
ERF	PE-2, PE2	ENSG00000105722	ETS2 repressor factor	19	42247572-42255157	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058532, HPA067952	Approved		Enhanced	Nucleoplasm	Breast cancer:8.07e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 78.9	Expressed in all		
RHBDL1	RHBDL, RRP	ENSG00000103269	Rhomboid like 1	16	675666-678268	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA030359, HPA030360, HPA046593	Uncertain		Approved	Nucleoplasm	Breast cancer:8.12e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 8.0	adrenal gland: 3.3	Mixed		
CYBA	p22-PHOX	ENSG00000051523	Cytochrome b-245 alpha chain	16	88643283-88651152	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB009492	Enhanced				Endometrial cancer:4.75e-5 (favourable), Renal cancer:1.83e-4 (unfavourable), Breast cancer:8.19e-4 (favourable)	Expressed in all	Expressed in all			spleen: 466.1	Cell line enhanced		RPMI-8226: 1035.0
KLK10	NES1, PRSSL1	ENSG00000129451	Kallikrein related peptidase 10	19	51012739-51020175	Cancer-related genes, Enzymes, Predicted secreted proteins	Evidence at protein level	HPA017195			Uncertain	Plasma membrane<br>Cytosol	Pancreatic cancer:6.46e-5 (unfavourable), Breast cancer:8.32e-4 (favourable)	Mixed	Tissue enhanced		esophagus: 138.2;skin: 52.7	tonsil: 45.8	Group enriched	5	CAPAN-2: 200.9;HaCaT: 307.2
SLC19A2	THTR1, TRMA	ENSG00000117479	Solute carrier family 19 member 2	1	169463909-169486003	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA006119, HPA016599	Uncertain		Approved	Cytosol	Renal cancer:2.70e-5 (favourable), Glioma:2.11e-4 (favourable), Breast cancer:8.41e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 49.2	Mixed		
THOC1	HPR1, P84	ENSG00000079134	THO complex 1	18	214520-268050	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019096, HPA019687	Enhanced		Enhanced	Nuclear speckles	Renal cancer:1.80e-6 (unfavourable), Liver cancer:1.83e-5 (unfavourable), Ovarian cancer:2.89e-5 (favourable), Breast cancer:8.43e-4 (favourable), Urothelial cancer:9.62e-4 (favourable)	Expressed in all	Mixed			testis: 29.3	Expressed in all		
LAMB3	BM600-125kDa, kalinin-140kDa, LAMNB1, nicein-125kDa	ENSG00000196878	Laminin subunit beta 3	1	209614870-209652466	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008069, CAB078183	Enhanced		Approved	Nucleoli<br>Mitochondria	Renal cancer:2.43e-5 (unfavourable), Lung cancer:9.62e-5 (unfavourable), Pancreatic cancer:2.55e-4 (unfavourable), Breast cancer:8.43e-4 (favourable)	Expressed in all	Mixed			stomach: 68.9	Cell line enhanced		CAPAN-2: 308.4;HaCaT: 470.9;HBEC3-KT: 935.2;hTCEpi: 295.3
RAPGEFL1	Link-GEFII	ENSG00000108352	Rap guanine nucleotide exchange factor like 1	17	40177010-40195656	Predicted intracellular proteins	Evidence at protein level	HPA022895			Approved	Nucleus<br>Microtubules<br>Cytokinetic bridge	Renal cancer:0.00e+0 (unfavourable), Cervical cancer:3.28e-4 (favourable), Breast cancer:8.43e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 277.1	esophagus: 93.2	Expressed in all		
MYD88		ENSG00000172936	Myeloid differentiation primary response 88	3	38138478-38143022	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009104	Approved		Supported	Vesicles<br>Mitochondria<br>Cytosol	Breast cancer:8.45e-4 (favourable)	Expressed in all	Mixed			lung: 57.1	Expressed in all		
BTG2	APRO1, MGC126063, MGC126064, PC3, TIS21	ENSG00000159388	BTG anti-proliferation factor 2	1	203305491-203309602	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA002355	Uncertain		Approved	Nucleoplasm<br>Vesicles	Breast cancer:8.53e-4 (favourable)	Expressed in all	Expressed in all			ovary: 666.8	Cell line enhanced		HMC-1: 140.5;U-266/70: 189.1
FCHSD1	FLJ00007	ENSG00000197948	FCH and double SH3 domains 1	5	141639302-141651419	Predicted intracellular proteins	Evidence at protein level	HPA043795	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.19e-6 (unfavourable), Urothelial cancer:1.21e-4 (favourable), Testis cancer:4.77e-4 (unfavourable), Breast cancer:8.62e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 41.1	Mixed		
XKR8	FLJ10307	ENSG00000158156	XK related 8	1	27959462-27968096	Predicted membrane proteins, Transporters	Evidence at protein level	HPA049984, HPA053529	Uncertain		Approved	Golgi apparatus	Breast cancer:8.63e-4 (favourable)	Expressed in all	Expressed in all			placenta: 13.7	Mixed		
GZMK	PRSS, TRYP2	ENSG00000113088	Granzyme K	5	55024253-55034570	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA063181	Enhanced				Renal cancer:1.06e-4 (unfavourable), Breast cancer:8.68e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 103.9	spleen: 41.9	Not detected		
METTL12	U99HG	ENSG00000214756	Methyltransferase like 12	11	62665309-62668496	Predicted intracellular proteins	Evidence at transcript level	HPA038115, HPA038533	Uncertain				Breast cancer:8.73e-4 (favourable)	Expressed in all	Not detected			fallopian tube: 0.8	Mixed		
SPDYE3		ENSG00000214300	Speedy/RINGO cell cycle regulator family member E3	7	100307702-100322196	Predicted intracellular proteins	Evidence at protein level	HPA051750	Supported				Endometrial cancer:2.00e-6 (unfavourable), Breast cancer:8.73e-4 (favourable)	Expressed in all	Tissue enriched	11	testis: 2.3	skin: 0.2	Not detected		
OLFM4	GC1, GW112, OlfD	ENSG00000102837	Olfactomedin 4	13	53028759-53052057	Predicted secreted proteins	Evidence at protein level	HPA077718	Enhanced				Breast cancer:8.77e-4 (favourable)	Group enriched	Tissue enhanced		duodenum: 1193.9;rectum: 611.5;small intestine: 1437.8	colon: 445.0	Cell line enhanced		BEWO: 5.1;BJ hTERT+: 15.0;HaCaT: 22.9
HHEX	HEX, HOX11L-PEN, PRHX	ENSG00000152804	Hematopoietically expressed homeobox	10	92689951-92695646	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051894, HPA055460	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:3.25e-5 (unfavourable), Cervical cancer:3.91e-5 (favourable), Liver cancer:6.23e-4 (unfavourable), Breast cancer:8.83e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 164.8	Cell line enhanced		HEL: 89.2;HMC-1: 92.9;HUVEC TERT2: 88.4;K-562: 137.7
CD274	B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1	ENSG00000120217	CD274 molecule	9	5450503-5470566	Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB030018, CAB076385	Enhanced		Approved	Cytosol	Colorectal cancer:1.64e-5 (favourable), Breast cancer:8.89e-4 (favourable)	Mixed	Mixed			appendix: 14.0	Cell line enhanced		HDLM-2: 82.8;HHSteC: 46.6;U-251 MG: 80.8
SERPINA3	AACT, ACT	ENSG00000196136	Serpin family A member 3	14	94612377-94624055	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000893, HPA002560, CAB016647	Enhanced				Breast cancer:8.92e-4 (favourable)	Mixed	Group enriched	6	cervix, uterine: 515.4;liver: 2304.3	gallbladder: 228.3	Cell line enriched	6	Hep G2: 302.6
RAB39B	MRX72	ENSG00000155961	RAB39B, member RAS oncogene family	X	155258241-155264589	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001114, HPA042505	Approved				Breast cancer:8.95e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 19.4	epididymis: 7.5	Cell line enhanced		Daudi: 19.2;Karpas-707: 24.8;SCLC-21H: 15.4;U-266/70: 26.3;U-266/84: 17.9
FAM69A	FLJ23493	ENSG00000154511	Family with sequence similarity 69 member A	1	92832737-92961522	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015718, HPA017281	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:1.45e-7 (unfavourable), Breast cancer:8.96e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 44.7	Mixed		
PLA2G4A	cPLA2-alpha, PLA2G4	ENSG00000116711	Phospholipase A2 group IVA	1	186828953-186988981	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010050, HPA050062, HPA054206	Approved		Supported	Cytosol	Endometrial cancer:2.85e-4 (favourable), Breast cancer:9.07e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 200.5	seminal vesicle: 68.3	Cell line enhanced		RPMI-8226: 50.7;U-2197: 61.7
CD247	CD3H, CD3Q, CD3Z	ENSG00000198821	CD247 molecule	1	167430640-167518610	CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB004651, HPA008750	Enhanced				Endometrial cancer:8.63e-6 (favourable), Renal cancer:9.94e-6 (unfavourable), Head and neck cancer:3.98e-4 (favourable), Breast cancer:9.12e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 65.1;spleen: 48.6	tonsil: 33.6	Group enriched	34	HDLM-2: 144.2;MOLT-4: 133.0
PNKP	PNK	ENSG00000039650	Polynucleotide kinase 3'-phosphatase	19	49859882-49878351	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006782	Supported		Supported	Nucleus<br>Nucleoli	Breast cancer:9.18e-4 (favourable)	Expressed in all	Expressed in all			spleen: 38.1	Expressed in all		
HYI	HT036	ENSG00000178922	Hydroxypyruvate isomerase (putative)	1	43451003-43453989	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040092	Uncertain		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Urothelial cancer:2.72e-5 (favourable), Renal cancer:2.75e-5 (unfavourable), Colorectal cancer:4.96e-4 (unfavourable), Liver cancer:5.55e-4 (unfavourable), Breast cancer:9.18e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 81.4	Mixed		
DIRAS3	ARHI, NOEY2	ENSG00000162595	DIRAS family GTPase 3	1	68045962-68051631	Predicted intracellular proteins	Evidence at protein level	HPA028483, HPA028557, HPA029384	Approved		Approved	Nuclear membrane<br>Cytosol	Breast cancer:9.21e-4 (favourable), Renal cancer:9.21e-4 (favourable)	Mixed	Tissue enhanced		ovary: 57.2	parathyroid gland: 20.5	Cell line enhanced		HSkMC: 9.3;TIME: 7.1;U-251 MG: 5.6;U-87 MG: 12.2
RPS9	S9	ENSG00000170889	Ribosomal protein S9	19	54200742-54249003	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA048746	Approved				Renal cancer:1.63e-4 (unfavourable), Breast cancer:9.23e-4 (favourable)	Expressed in all	Expressed in all			ovary: 112.4	Expressed in all		
SNRK	FLJ20224, HSNFRK, KIAA0096	ENSG00000163788	SNF related kinase	3	43286512-43424764	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042163	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cell Junctions	Renal cancer:9.41e-5 (favourable), Breast cancer:9.28e-4 (favourable)	Expressed in all	Expressed in all			placenta: 47.8	Expressed in all		
MYO15B	MYO15BP	ENSG00000266714	Myosin XVB	17	75588058-75626501	Predicted intracellular proteins	Evidence at transcript level	HPA022857, HPA023105			Approved	Cytosol	Urothelial cancer:6.90e-5 (favourable), Breast cancer:9.34e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 148.3	Cell line enhanced		A549: 36.9;HMC-1: 21.7;THP-1: 24.6
ANKRD35	FLJ25124	ENSG00000198483	Ankyrin repeat domain 35	1	145866560-145885866	Predicted intracellular proteins	Evidence at protein level	HPA035453	Enhanced				Cervical cancer:2.90e-4 (favourable), Breast cancer:9.35e-4 (favourable)	Mixed	Group enriched	6	cervix, uterine: 30.8;esophagus: 16.6;skin: 69.8	tonsil: 6.1	Cell line enhanced		ASC TERT1: 6.6;THP-1: 4.5;TIME: 6.9;U-87 MG: 8.1;U-937: 5.9
FOXJ1	FKHL13, HFH-4, HFH4	ENSG00000129654	Forkhead box J1	17	76136333-76141299	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005714	Enhanced				Renal cancer:2.03e-5 (unfavourable), Breast cancer:9.39e-4 (favourable)	Tissue enhanced	Tissue enriched	8	fallopian tube: 83.6	lung: 10.3	Group enriched	10	BEWO: 28.2;CAPAN-2: 21.8
SLAMF6	CD352, KALI, KALIb, Ly108, NTB-A, NTBA, SF2000	ENSG00000162739	SLAM family member 6	1	160485030-160523262	CD markers, Predicted membrane proteins	Evidence at protein level	HPA051363, HPA051903	Uncertain				Renal cancer:2.09e-6 (unfavourable), Head and neck cancer:7.34e-5 (favourable), Melanoma:1.25e-4 (favourable), Cervical cancer:2.78e-4 (favourable), Breast cancer:9.42e-4 (favourable), Endometrial cancer:9.53e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 70.8;spleen: 43.3;tonsil: 44.6	appendix: 27.2	Cell line enhanced		Daudi: 63.2;MOLT-4: 17.4;U-698: 89.3
KRT6B	KRTL1	ENSG00000185479	Keratin 6B	12	52446651-52452126	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000130, HPA045697, HPA061168	Supported		Approved	Intermediate filaments	Breast cancer:9.44e-4 (favourable), Urothelial cancer:9.52e-4 (unfavourable)	Tissue enhanced	Tissue enriched	10	esophagus: 670.7	tonsil: 67.0	Cell line enhanced		HBEC3-KT: 19.9;hTCEpi: 21.8;RPMI-8226: 9.3
ZNF326	FLJ20403, ZAN75, Zfp326, ZIRD	ENSG00000162664	Zinc finger protein 326	1	89995112-90035531	Predicted intracellular proteins	Evidence at protein level	HPA028450, HPA028461, HPA028466	Supported		Enhanced	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Urothelial cancer:2.84e-4 (favourable), Breast cancer:9.46e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 29.5	Expressed in all		
SLC8B1	FLJ22233, NCKX6, NCLX, SLC24A6	ENSG00000089060	Solute carrier family 8 member B1	12	113298759-113359493	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA040668	Approved				Urothelial cancer:5.02e-4 (favourable), Breast cancer:9.52e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 48.4	Mixed		
LCN2	24p3, NGAL	ENSG00000148346	Lipocalin 2	9	128149071-128153455	Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA002695, CAB016549, CAB016550	Enhanced		Supported	Endoplasmic reticulum	Breast cancer:9.61e-4 (favourable)	Mixed	Tissue enhanced		bone marrow: 1852.1;gallbladder: 3419.4	cervix, uterine: 1163.5	Group enriched	11	CAPAN-2: 3169.5;EFO-21: 1362.3
JAK1	JAK1A, JAK1B, JTK3	ENSG00000162434	Janus kinase 1	1	64833229-64966504	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013088	Approved				Renal cancer:2.67e-4 (favourable), Colorectal cancer:2.81e-4 (favourable), Breast cancer:9.63e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 115.6	Expressed in all		
ETFRF1	LYRM5	ENSG00000205707	Electron transfer flavoprotein regulatory factor 1	12	25195216-25209645	Predicted intracellular proteins	Evidence at protein level	HPA044255	Approved		Approved	Microtubule organizing center	Renal cancer:9.23e-5 (favourable), Breast cancer:9.63e-4 (favourable)	Expressed in all	Expressed in all			testis: 112.5	Expressed in all		
BCL3	BCL4, D19S37	ENSG00000069399	B-cell CLL/lymphoma 3	19	44747705-44760044	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002051, HPA047514	Approved		Supported	Nucleoplasm<br>Vesicles<br>Midbody	Renal cancer:3.13e-14 (unfavourable), Melanoma:3.74e-4 (favourable), Glioma:5.58e-4 (unfavourable), Breast cancer:9.67e-4 (favourable)	Expressed in all	Expressed in all			appendix: 30.1	Cell line enhanced		HDLM-2: 55.4;SiHa: 65.8
RPS27	MPS-1, MPS1, S27	ENSG00000177954	Ribosomal protein S27	1	153990759-153992150	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA066851			Approved	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:4.86e-7 (unfavourable), Breast cancer:9.69e-4 (favourable)	Expressed in all	Expressed in all			ovary: 12000.9	Expressed in all		
BRICD5	C16orf79, MGC21830	ENSG00000182685	BRICHOS domain containing 5	16	2209253-2211950	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019197, HPA063522	Uncertain		Approved	Nucleoplasm<br>Actin filaments	Urothelial cancer:8.06e-5 (favourable), Pancreatic cancer:7.01e-4 (favourable), Breast cancer:9.74e-4 (favourable)	Expressed in all	Mixed			testis: 10.6	Mixed		
IL3RA	CD123	ENSG00000185291	Interleukin 3 receptor subunit alpha	X	1336616-1382689	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003539, CAB018374	Approved				Cervical cancer:4.27e-4 (favourable), Breast cancer:9.78e-4 (favourable)	Expressed in all	Mixed			lung: 33.2	Cell line enhanced		HDLM-2: 109.2;RPMI-8226: 33.2
LTA4H		ENSG00000111144	Leukotriene A4 hydrolase	12	96000828-96043520	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008399, CAB015221, HPA017017	Supported		Supported	Nucleoplasm<br>Cytosol	Lung cancer:8.96e-4 (favourable), Breast cancer:9.79e-4 (favourable)	Expressed in all	Expressed in all			lung: 283.5	Expressed in all		
ZNF512	KIAA1805	ENSG00000243943	Zinc finger protein 512	2	27582969-27623215	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031430	Approved		Enhanced	Nucleus	Lung cancer:5.08e-9 (favourable), Endometrial cancer:5.10e-4 (unfavourable), Pancreatic cancer:5.19e-4 (favourable), Breast cancer:9.79e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 45.7	Mixed		
RPS18	D6S218E, HKE3, KE-3, KE3, S18	ENSG00000231500	Ribosomal protein S18	6	33272010-33276510	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA050159, HPA055007	Approved		Supported	Cytosol	Renal cancer:1.15e-10 (unfavourable), Breast cancer:9.81e-4 (favourable)	Expressed in all	Expressed in all			ovary: 1305.1	Expressed in all		
AP1S2	MRX59, MRXS5, PGS, SIGMA1B	ENSG00000182287	Adaptor related protein complex 1 sigma 2 subunit	X	15825806-15855014	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049894, HPA060945	Enhanced		Supported	Golgi apparatus<br>Vesicles	Ovarian cancer:5.53e-6 (favourable), Breast cancer:9.86e-4 (favourable)	Expressed in all	Tissue enriched	7	epididymis: 920.5	smooth muscle: 126.9	Expressed in all		
PCSK6	PACE4, SPC4	ENSG00000140479	Proprotein convertase subtilisin/kexin type 6	15	101297142-101525202	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004774	Uncertain				Renal cancer:7.06e-7 (unfavourable), Breast cancer:9.99e-4 (favourable)	Mixed	Tissue enhanced		liver: 90.3;spleen: 124.6	placenta: 53.9	Cell line enhanced		BEWO: 57.8;HEK 293: 58.5;Hep G2: 39.9
HSD17B8	D6S2245E, FABGL, H2-KE6, HKE6, KE6, RING2, SDR30C1	ENSG00000204228	Hydroxysteroid 17-beta dehydrogenase 8	6	33204642-33206831	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042132	Enhanced				Renal cancer:2.18e-12 (favourable), Liver cancer:1.90e-5 (favourable), Breast cancer:9.99e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 9.9	Cell line enhanced		RPMI-8226: 11.7;T-47d: 9.9;U-266/70: 12.1
